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REASSESSING SAFETY FOR NANOTECHNOLOGY COMBINATION 
PRODUCTS: WHAT DO BIOSIMILARS ADD TO REGULATORY 
CHALLENGES FOR THE FDA? 
JORDAN PARADISE* 
ABSTRACT 
Amidst sweeping changes to the United States health care system ushered 
in by the Patient Protection and Affordable Care Act (“ACA”), the Food and 
Drug Administration (“FDA”) continues to struggle to apply often centuries-
old product categorizations to emerging technological innovations.  The 
ACA’s introduction of a “biosimilar” pathway to market for biological 
products, modeled on abbreviated pathways to market for drugs and medical 
devices, further complicates the assessment of “safety” and measures of 
equivalence and similarity that allow products to enter the market faster.  One 
area where this is particularly acute is nanobiotechnology, which has enabled a 
set of products that drift uncomfortably at the interface of drugs, medical 
devices, and biologics, blending unique and novel biological properties at the 
nanoscale that integrate chemical, mechanical, and biological aspects into a 
wide range of consumer medical and health care products. 
This Article will argue that the creation of the biosimilar pathway will 
prove to be the straw that breaks the camel’s back unless the FDA develops 
new dynamic models to properly assess and regulate nanomedical combination 
products.  This Article will examine the existing frameworks of FDA oversight 
for medical and health care products, highlight nanotechnology (and 
nanobiotechnology and nanomedicine) specifically as an area where products 
are currently straddling traditional boundaries between FDA product 
categories, discuss recent FDA initiatives and Agency procedures regarding 
nanotechnology, and will suggest an approach for the FDA to respond to 
nanobiotechnology, including more effective federal coordination; 
reorganization of the FDA either through congressional action or 
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Commissioner action in order to properly classify, assess, monitor, and 
regulate emerging nanomedical technologies and products; and changes to 
FDA policy regarding data requirements and post-market reporting from 
industry to address concerns about the scope of safety in the context of 
nanomedical products. 
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INTRODUCTION 
The Patient Protection and Affordable Care Act (“ACA”)1 brought 
sweeping changes to the U.S. health care system, triggering immediate 
challenges to the constitutionality of the legislation and seemingly limitless 
questions regarding its practical implementation.  The ACA also ushered in a 
new era for the oversight of biological products within the purview of the U.S. 
Food and Drug Administration (“FDA”), creating a pathway for approval of 
products that are “biosimilar” or “interchangeable” with an existing biological 
product (“biologic”).2  In doing so, Congress has deposited a major regulatory 
challenge in front of the FDA during a time in which the FDA faces daily 
onslaught for its perceived inability to assure safety and efficacy of drug and 
medical device products.3  This challenge is amplified by advancements at the 
intersection of nanotechnology and medicine and health care, which pose novel 
problems for safety assessment of drugs, medical devices, and biologics. 
Product classification is a touchstone of regulation by the FDA.  The 
classification of a new medical advancement as a drug, medical device, or 
biologic determines the FDA center to which it is allocated and therefore 
which approval process it will follow.4  This, in turn, determines the financial 
investment required to bring it to market and the extent and type of 
requirements imposed on industry, particularly requirements governing 
measures of safety to ensure that benefits outweigh risks for each product.  
Each route to market has its own requirements and process and its own set of 
ensuing controversies.5  Recent high-profile product recalls, outcry over 
improper scientific data, and challenges to the adequacy of post-market 
monitoring have plagued the FDA in the context of drug and biologic 
oversight.6  Medical device oversight has similarly been subject to increased 
scrutiny by Congress and the Institute of Medicine (“IOM”) with regard to the 
FDA’s overwhelming use of the 510(k) clearance process rather than requiring 
full-scale safety and efficacy review and approval.7  The FDA’s assessment 
and treatment of scientific and technical information guides oversight of 
product areas, dependent largely on sometimes-irrational categorical and 
 
 1. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119 (2010) 
(codified in scattered sections of the U.S. Code). 
 2. Id. § 7002(b), 42 U.S.C. §§ 262(i)(2)–(3) (Supp. IV 2010). 
 3. See, e.g., INST. OF MED., MEDICAL DEVICES AND THE PUBLIC’S HEALTH: THE FDA 
510(K) CLEARANCE PROCESS AT 35 YEARS 193 (2011). 
 4. See infra Part II.A–D. 
 5. See infra Part II.A–D. 
 6. See, e,g., infra Parts II.A, II.C. 
 7. See INST. OF MED., supra note 3, at 4; infra Part II.B. 
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definitional divisions that structure the Food, Drug, and Cosmetic Act 
(“FDCA”).8 
Recognizing the swift integration of drug, device, and biologic elements in 
medical and health care advancements, Congress created the FDA’s Office of 
Combination Products (“OCP”) to assess emerging technologies at the 
interface of these three product realms.9  The OCP classifies a product as a 
drug, medical device, or biologic according to its “primary mode of action,” 
directing it to the appropriate FDA Center and route to market based on this 
determination.10  The combination product process itself faces ongoing 
criticisms, flowing both from perceived shortcomings in the three product 
classifications (drug, device, or biologic), and the resulting silo effect of the 
FDA’s determination for products that integrate chemical, biological, and 
mechanical mechanisms of action in often novel and innovative ways.11 
Congress has now added yet another layer to the FDA’s regulatory 
challenge with the enactment of the recent health care legislation.  The 
Biologics Price Competition and Innovation Act of March 201012 (part of the 
ACA) creates an additional route to market for biologics—the “follow-on” or 
“biosimilar” biologics approval pathway—and gives broad implementation 
authority to the FDA.13  The creation of this biosimilar pathway, coupled with 
the abbreviated pathways to market for both drugs (the abbreviated new drug 
approval pathway) and medical devices (the 510(k) clearance process), and the 
combination products mechanism, poses significant implementation challenges 
for the FDA. 
It is now useful to take one step back and ask: is the “combination 
products” approach and availability of abbreviated routes to market the right 
conceptual framework to assure product safety for new, category-busting 
products?  One area that highlights the effects of category confusion is 
nanomedicine, the interface of nanotechnology with human health and 
medicine, where emerging products promise to combine aspects of two or even 
all three product areas.  Utilizing scientific and technical properties of 
nanotechnology, medical innovations are now pressing the traditional bounds 
of the FDA’s product classification scheme, integrating multiple and dynamic 
 
 8. Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as 
amended in scattered sections of 21 U.S.C.). 
 9. See infra Part II.D. 
 10. See infra Part II.D. 
 11. See, e.g., Susan Bartlett Foote & Robert J. Berlin, Can Regulation be as Innovative as 
Science and Technology? The FDA’s Regulation of Combination Products, 6 MINN. J.L. SCI. & 
TECH. 619, 622–23, 631, 640–41 (2005). 
 12. Pub. L. No. 111-148, §§ 7001–03, 124 Stat. 119, 804–21 (2010) (codified in scattered 
sections of 42 U.S.C. & 21 U.S.C. (Supp. IV 2010)). 
 13. 42 U.S.C. §§ 262(k)(8)(A)–(B) (Supp. IV 2010). 
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features.14  While U.S. federal agencies are busy grappling with the science 
and scope of nanotechnology, research and development is swiftly moving 
forward.15  As the gatekeeper to entrance of most medical and health care 
products to the U.S. market, the FDA will play a large role in assessing the 
applications of nanomedicine. 
This Article will argue that the creation of the biosimilar pathway will 
prove to be the straw that breaks the camel’s back unless the FDA develops 
new dynamic models to properly assess and regulate nanomedical combination 
products.  This Article will examine the existing frameworks of FDA oversight 
for medical and health care products, highlight nanotechnology (and 
nanobiotechnology and nanomedicine) specifically as an area where products 
are currently straddling traditional boundaries between FDA product 
categories, discuss recent FDA initiatives and agency procedures regarding 
nanotechnology, and will suggest an approach for the FDA to respond to 
nanobiotechnology, which has enabled a set of products that drift 
uncomfortably at the interface of drugs, medical devices, and biologics. 
Part I will situate nanomedicine within the “nano” landscape, setting out its 
scope and relationship to other technologies.  Part II will examine the 
traditional oversight frameworks of the FDA for drugs, biologics, and medical 
devices; address the role of the FDA in protecting public health and safety in 
development and use of those innovations in medicine and health care; and 
identify key statutory provisions and regulations in the FDA realm.  This part 
will also identify core challenges and concerns regarding abbreviated routes to 
market available for these types of products—the abbreviated new drug 
approval process for drugs, the 510(k) process for medical devices, and the 
newly created “biosimilar” and “interchangeable” route for biologics.  It will 
also set forth the framework for combination products, a streamlining process 
tied directly to the drug, medical device, and biologic pathways.  Part III will 
examine the responses of the FDA to nanotechnology developments, including 
the initiation of an agency-wide nanotechnology task force, internal policy 
changes to gather nano-specific information from new drug applications, draft 
guidance to industry on considerations for nanotechnology products, increased 
requests for public comment and public meetings for input on specific aspects 
of nanotechnology, and research partnerships.  Part IV will then suggest 
several approaches for the FDA to pursue in overseeing emerging products 
blending drug, medical device, and biological aspects.  These suggestions 
include more effective use of the National Nanotechnology Initiative (“NNI”), 
 
 14. Jordan Paradise et al., Exploring Emerging Nanobiotechnology Drugs and Medical 
Devices, 63 FOOD & DRUG L.J. 407, 417–20 (2008). 
 15. See, e.g., KK Jain, Advances in the Field of Nanooncology, BMC MEDICINE, Dec. 13, 
2010, at 1, http://www.biomedcentral.com/content/pdf/1741-7015-8-83.pdf (discussing advances 
in the use of nanotechnology in cancer treatment). 
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the federal body tasked with aiding in nanotechnology research and 
development, not only to promote and fund research but also to facilitate 
collaboration on topics of oversight; reorganization of the FDA either through 
congressional action or Commissioner action in order to properly classify, 
assess, monitor, and regulate emerging nanomedical technologies and 
products; and changes to FDA policy regarding data requirements and post-
market reporting from industry to address concerns about the scope of safety in 
the context of nanomedical products.  This will be followed by a brief 
conclusion. 
I.  SITUATING NANOMEDICINE IN THE NANO SPECTRUM 
A. The Nanoscale and Nanotechnology 
The nanoscale is the scale range below the microscale—traditionally 
measured as under 100nm (or 10-9m, or one billionth of a meter).16  Scientists 
and commentators have found interesting ways to illustrate this scale in a 
manner comprehensible to the general public, including comparing the 
nanoscale to the width of a human hair (where a strand of human hair is 
approximately 40,000 nm in diameter)17 or the thickness of a sheet of paper 
(where a sheet of paper is 100,000 nm thick).18  Simply put, nanoscale is all 
about the size. 
The term nanotechnology encompasses an array of technologies at the 
nanoscale.  The NNI defines “nanotechnology” as involving three inter-related 
(and inseparable) aspects: (1) “[r]esearch and technology development at the 
atomic, molecular or macromolecular levels, in the length scale of 
approximately 1–100 nanometer” range; (2) “creat[ing] and us[ing] [] 
structures, devices and systems that have novel properties and functions 
because of their small and/or intermediate sizes”; and (3) “ability to be 
controlled or manipulated on the atomic scale.”19  Thus, a key feature of 
nanotechnology is that while size matters, it is not everything.  To be truly 
nanotechnology, unique physical, chemical, and/or biological properties must 
be present at the nanoscale that make the particle or material function in a 
manner that can be harnessed and controlled to utilize those unique 
properties.20  Thus, rather than merely connoting size, nanotechnology is all 
 
 16. NAT’L INST. OF STANDARDS & TECH., U.S. DEP’T OF COMMERCE, INTERNATIONAL 
SYSTEM OF UNITS (SI) 29 (Barry N. Taylor & Ambler Thompson eds., 2008). 
 17. Nanotechnology Basics, NANOTECHNOLOGY NOW, http://www.nanotech-now.com/ba 
sics.htm (last updated June 27, 2009). 
 18. Nat’l Nanotechnology Initiative, Size of the Nanoscale, NANO.GOV, http://www.nano. 
gov/nanotech-101/what/nano-size (last visited Nov. 22, 2011). 
 19. U.S. ENVTL. PROT. AGENCY, NANOTECHNOLOGY: AN EPA RESEARCH PERSPECTIVE 
FACTSHEET (2007), available at http://epa.gov/ncer/nano/factsheet/nanofactsheetjune07.pdf. 
 20. Id. 
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about how the size contributes to unique and controllable properties and 
functions. 
Two other variations of the “nanotechnology” definition will factor into 
discussions later in this Article.  While all twenty-five agencies that make up 
the NNI support the NNI definition, many have adapted it to deal with product 
or process-specific issues facing that Agency.  For example, the FDA’s Center 
for Drug Evaluation and Research (“CDER”) hinges its scope of 
nanotechnology to nanomaterials and nanoscale materials, which the Agency 
defines as “any materials with at least one dimension smaller than 1,000 nm.”21  
While the FDA acknowledges consultation of the existing NNI definition,22 the 
CDER chose to designate the nanoscale as exceeding the traditionally 
delineated 100 nm maximum by a tenfold difference, perhaps because the 
Agency is observing drug products utilizing novel properties at numbers higher 
than 100nm and prefers to be over-inclusive, rather than under-inclusive for 
long-term tracking purposes.  In fact, Abraxane, one of the first marketed 
nanodrugs, has a 130nm mean particle size;23 other products may deviate from 
the 100nm ceiling depending on the size of the actual drug product compared 
to the total size of the particle containing the drug product and any 
encapsulating material or adjuvant.24 
The term nanotechnology itself and its use in scientific circles have 
evolved.  First entering into the technical and scientific lexicon in 1974, the 
term “nano-technology” described the process of scaling down to an advanced 
level of precision in the field of engineering (known as the “top-down 
approach”)25; the term was further applied by K. Eric Drexler, a renowned 
physicist, in 1986 to describe the scaling up of particles (known as the 
 
 21. CTR. FOR DRUG EVALUATION AND RESEARCH, U.S. FOOD & DRUG ADMIN.,  MANUAL 
OF POLICIES AND PROCEDURES 5015.9: REPORTING FORMAT FOR NANOTECHNOLOGY-RELATED 
INFORMATION IN CMC REVIEW 3 (2010) [hereinafter MAPP 5015.9 REPORTING FORMAT], 
available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ManualofPolicies 
Procedures/UCM214304.pdf. 
 22. Id. at 7.  Attachment B is titled “Search Terms for Populating the CDER 
Nanotechnology Drug Product Database” and includes the National Nanotechnology Initiative 
definition of “nanotechnology” as well as related definitions from professional organizations, the 
FDA itself, scholarly scientific publications, and textbooks.  Id. 
 23. See ABRAXIS BIOSCIENCE, INC., ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING 
BRIEFING PACKAGE: ABRAXANE 5 (2006), available at http://www.fda.gov/ohrms/dockets/ac/06/ 
briefing/2006-4235B2-01-01AbraxisBioscience-background.pdf. 
 24. Draft Guidance for Industry: Considering Whether an FDA-Regulated Product Involves 
the Application of Nanotechnology, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Regulatory 
Information/Guidances/ucm257698.htm (last visited Jan. 22, 2011) [hereinafter Draft Guidance 
for Industry]. 
 25. Norio Taniguchi, On the Basic Concept of ‘Nano-Technology’, 2 PROC. OF THE INT’L 
CONF. ON PRODUCTION ENGINEERING 18, 18 (1974). 
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“bottom-up approach”).26 Today, both top-down and bottom-up processes are 
employed in order to arrive at the nanoscale and the unique properties that 
emerge at that size; the choice of approaches varies by material and scientific 
discipline.27  Unique nanoscale properties include electrical, where nanoscale 
particles and materials can hold considerably more energy than conventional 
sized materials because of their large surface area (e.g., carbon nanotubes 
(“CNTs”) have an increased efficiency at conducting heat—carbon becomes a 
superconductor at the nanoscale);28 optical, where linear and nonlinear optical 
properties can be finely tailored by controlling the crystal dimensions and 
surface chemistry (e.g., gold nanoparticles and quantum dots);29 chemical, 
where nanoparticles can be used as catalysts30 and exhibit enhanced chemical 
activity (e.g., silver at the nanoscale excels as an antimicrobial germ-killer and 
nanoscale particles for drug delivery can cross into tumor vasculatures);31 and 
mechanical, where nanomaterials exhibit increased hardness, fracture 
toughness, scratch resistance, and fatigue strength (e.g., CNTs and C60 
fullerenes).32 
Depending on the particular area of development, nanotechnology may 
include the use of nano-sized technology or processes to create specific 
products or applications, the inclusion of nano-sized particles or materials, or 
both.  Products on the market that claim to be nanotechnology include 
aerosols, pesticides and chemicals, air filtration systems, medical devices (such 
as dental adhesives and diagnostic systems), robotics, pharmaceuticals, 
cosmetics, and coatings and materials integrated into a wide variety of 
consumer products (such as antibacterial coatings on wound dressings and 
baby products, stain-resistant pants, high durability tennis rackets, and no-stick 
 
 26. K. ERIC DREXLER, ENGINES OF CREATION 3–20 (1986). 
 27. O. G. Schmidt et al., Nanotechnology—Bottom-up Meets Top-down, in 42 ADVANCES IN 
SOLID STATE PHYSICS 231, 231–32 (Bernhard Kramer ed., 2002). 
 28. See, e.g., Ray H. Baughman et al., Carbon Nanotubes—The Route Toward Applications, 
297 SCI. 787, 787, 791 (2002); Younan Xia et al., One-Dimensional Nanostructures: Synthesis, 
Characterization, and Applications, 15 ADVANCED MATERIALS 353 (2003). 
 29. Xiaohu Gao et al., In Vivo Cancer Targeting and Imaging with Semiconductor Quantum 
Dots, 22 NATURE BIOTECHNOLOGY 969 (2004). 
 30. See, e.g., Robert W. J. Scott et al., Synthesis, Characterization, and Applications of 
Dendrimer-Encapsulated Nanoparticles, 109 J. PHYSICAL CHEMISTRY B 692, 696–702 (2005). 
 31. See, e.g., Döne Demirgöz et al., PR_b-Targeted PEGylated Liposomes for Prostate 
Cancer Therapy, 24 LANGMUIR 13,518 (2008); Ashish Garg et al., Targeting Colon Cancer Cells 
Using PEGylated Liposomes Modified with a Fibronectin-Mimetic Peptide, 366 INT’L J. 
PHARMACEUTICS 201 (2009); Todd O. Pangburn et al., Peptide- and Aptamer-Functionalized 
Nanovectors for Targeted Delivery of Therapeutics, J. BIOMECHANICAL ENGINEERING, July 
2009, at 074005-1, 074005-2. 
 32. Erik T. Thostenson et al., Advances in the Science and Technology of Carbon Nanotubes 
and Their Composites: A Review, 61 COMPOSITES SCI. AND TECH. 1899, 1899, 1905–07 (2001). 
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cooking pans).33  It is often impossible to discern whether they are truly 
nanotechnology products or whether the marketing claims are merely painting 
the product in a space-age light. 
As compared to the three-pronged NNI definition of nanotechnology, the 
prefix “nano” is typically used to denote anything at the scale of under 100nm, 
independent of whether there are novel characteristics or functions and an 
ability to control.  For example, materials and particles at the nanoscale are 
called such terms as nanomaterials and nanoparticles, indicating merely that 
they exist at the scale range under 100nm.34  The lesson to take away from this 
is that not everything “nano” (think size) is “nanotechnology” (think size, plus 
novel properties, plus ability to control). 
Nanotechnology has garnered much attention from the federal government, 
enjoying considerable funding and publicity which only promises to increase 
as the technologies advance. In fact, the actual 2011 NNI budget provided 
$1.85 billion in funding that supports nanoscale science and engineering 
research and development spread across fifteen federal agencies.35  The 
cumulative federal investment in nanotechnology through the NNI since 2001 
is approximately $14 billion.36 
 
 33. The Woodrow Wilson Center’s Nanotechnology Consumer Products Inventory is a 
useful resource that collects information on the “nano” marketing claims of consumer products 
both in the United States and internationally.  Woodrow Wilson International Center for Scholars, 
Nanotechnology Consumer Products Inventory, NANOTECHPROJECT.ORG, http://www.nanotech 
project.org/inventtories/consumer/ (last visited Nov. 30, 2011).  The Inventory divides products 
into multiple categories, including appliances, automotive, electronics and computers, food and 
beverage, children’s goods, health and fitness, and home and garden.  Id.  While all of these 
products share the common thread that the manufacturer or other source touts that they contain or 
utilize “nanotechnology,” this is not necessarily the case. 
 34. See Nanotechnology Basics, supra note 17.  The word “nano” is commonly related to a 
Greek word meaning “dwarf.”  Christian Joachim, To Be Nano or Not to Be Nano?, 4 NATURE 
MATERIALS 107, 108 (2005). 
 35. Nat’l Nanotechnology Initiative, NNI Budget, NANO.GOV, http://www.nano.gov/about-
nni/what/funding (last visited Nov 30, 2011).  The largest investments have been delivered to the 
Department of Energy (energy technologies), National Science Foundation (science and 
engineering generally), National Institutes of Health (biomedical research in the life and physical 
sciences), the Department of Defense (defense and dual-use capabilities), and the National 
Institute of Standards and Technology (measurement and fabrication tools, analytical 
methodologies, and metrology).  Id. 
 36. NNI Strategic Plan 2010; Request for Information, 75 Fed. Reg. 38,850, 38,851 (July 6, 
2010).  The total, including the NNI’s 2012 requests, would be $16.5 billion since 2001.  
SUBCOMM. ON NANOSCALE SCI., ENG’G, & TECH., NAT’L SCI. & TECH. COUNCIL, THE 
NATIONAL NANOTECHNOLOGY INITIATIVE: RESEARCH AND DEVELOPMENT LEADING TO A 
REVOLUTION IN TECHNOLOGY AND INDUSTRY: SUPPLEMENT TO THE PRESIDENT’S 2012 BUDGET 
7 (2011), available at http://nano.gov/NNI_2012_budget_supplement.pdf. 
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B. The Nano/Bio Interface and “Nanomedicine” 
Nanobiotechnology is a narrower application of nanotechnology—“a field 
that applies the nanoscale principles and techniques to understand and 
transform biosystems (living or non-living) and which uses biological 
principles and materials to create new devices and systems integrated from the 
nanoscale.”37  This is essentially the application of nanotechnology to living 
systems or the use of nanotechnology to create systems that mimic living 
systems; this marriage makes inherent sense as biological cells and systems 
often exist at the nanoscale naturally.  For example, the largest amino acid 
(tryptophan) measures 1.2nm,38 ribosomes measure approximately 2–4nm,39  
DNA measures 2.5nm in width,40 and proteins typically measure between 1–
20nm.41 
Given the natural relationship between the nanoscale and internal 
properties and functioning of the human body, improvement of human health 
and advancements in medicine are prime targets for nanotechnology.42  The 
unique and far-ranging properties of nanostructures and nanotechnology have 
facilitated breakthroughs in the pharmaceutical and medical device realms—a 
confluence termed nanomedicine.43  The National Institutes of Health (“NIH”) 
defines nanomedicine as a “highly specific medical intervention at the 
molecular scale for curing disease or repairing damaged tissues, such as bone, 
muscle, or nerve.”44  The FDA defines nanomedicine as “[t]he use of 
nanoscale materials for medical applications.”45  Nanomedicine is a vastly 
growing field in the United States, with projections that the market will reach 
$53 billion in 2011.46  Massive amounts of federal funding are being directed 
to nanomedicine research through the NNI—the NIH alone devoted $200 
million to nanotechnology research in 2008.47  Many biological phenomena 
 
 37. Mihail C. Roco, Nanotechnology: Convergence with Modern Biology and Medicine, 14 
CURRENT OPINION BIOTECHNOLOGY 337, 337 (2003). 
 38. KEWAL K. JAIN, THE HANDBOOK OF NANOMEDICINE 3 tbl.1.2 (2008). 
 39. Id. 
 40. Id. 
 41. Id. 
 42. See, e.g., Volker Wagner et al., The Emerging Nanomedicine Landscape, 24 NATURE 
BIOTECHNOLOGY 1211, 1215, 1217 (2006). 
 43. Id. at 1212. 
 44. Nanomedicine: Overview, NAT’L INST. OF HEALTH COMMON FUND, http://common 
fund.nih.gov/nanomedicine/overview.aspx (last updated Jan. 1, 2011). 
 45. MAPP 5015.9 REPORTING FORMAT, supra note 21, at 3. 
 46. Raj Bawa & Summer Johnson, The Ethical Dimensions of Nanomedicine, 91 MED. 
CLINICS N. AM. 881, 882 (2007) (citing Freedonia Grp., NANOTECHNOLOGY IN HEALTHCARE 
(2007)). 
 47. NANOTECHNOLOGY TASK FORCE, NAT’L INSTS. OF HEALTH, 2008 STATEMENT OF 
PURPOSE (2008), available at http://www.nibib.nih.gov/nibib/file/Research/Nanotechnology/ 
NIH_Nanotechnology_Task_Force_Plan_FINAL_Jan09.pdf. 
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naturally occur at the nanoscale; however, nanomedicine refers to materials or 
particles fabricated at this scale to take advantage of manifest properties (e.g., 
optical, chemical, and mechanical).48  Products at the nanoscale are emerging 
that utilize and integrate nanoscale properties, have the ability to mimic 
biological systems, and will, in time, be able to functionally evolve in response 
to bodily feedback. 
Research at the nanoscale illustrates that as particle size decreases, and 
surface area increases, the biological activity of particles increases.49  The 
resulting unique physical properties at the nanoscale are extremely promising 
for medical applications in that they may solve some of the most difficult 
barriers for effective therapeutics and diagnostics.50  In terms of in vitro and in 
vivo imaging, nanoscale properties involving optical absorbance, fluorescence, 
and electrical and magnetic conductivity are key to locate and visualize 
internal functioning;51 for drug delivery and formulation of drugs, nanoscale 
properties involving pharmacokinetics, biodistribution, and cell permeability 
will assist in getting the drug load to the exact location, and faster;52 and for 
implants, bone and dental restoratives, and coatings for wound care and 
various other applications, the size and shape, surface modification, and direct 
interaction with tissues will increase efficacy.53  The interface of nanomedicine 
and nanobiotechnology has introduced widespread research activity in the 
areas of biomolecule and biomimetic devices, biosensors, molecular motors, 
biomolecular fabrics, engineered enzymes and proteins, and drug discovery 
and delivery.54 
As will be discussed in Part III, little to nothing is yet known about the 
health, safety, and environmental impacts of nanomaterials and nanoparticles.  
Scientists and regulators alike are struggling to quantify and characterize these 
materials in an effort to create appropriate toxicological testing and assessment 
tools.55  Specific to human safety and public health, there are broad questions 
 
 48. Nanomedicine: Overview, supra note 44. 
 49. Andre Nel et al., Toxic Potential of Materials at the Nanolevel, 311 SCI. 622, 622 
(2006); see also Andre E. Nel et al., Understanding Biophysicochemical Interactions at the Nano-
Bio Interface, 8 NATURE MATERIALS 543, 554 (2009) (discussing particle size, surface area, and 
bioreactivity in the context of pulmonary inflammation). 
 50. Nagender Reddy Panyala et al., Gold and Nano-Gold in Medicine: Overview, Toxicology 
and Perspectives, 7 J. APPLIED BIOMEDICINE 75, 75 (2009). 
 51. Id. at 76–77, 84. 
 52. Pawan Malhotra & Aneeta Singh, Nano Medicine—A Futuristic Approach, 12 JK SCI. 3, 
3 (2010), http://www.jkscience.org/current/Nano%20Medicine-%20A%20Futuristic%20Ap 
proach.pdf. 
 53. See id. at 4 (noting that nanomachines that enter cells are able to more effectively make 
“modifications of faulty [cell] structure”). 
 54. Alan L. Porter et al., Refining Search Terms for Nanotechnology, 10 J. NANOPARTICLE 
RES. 715, 718 fig.1 (2008). 
 55. See infra Part II. 
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about the toxicity of nanoparticles in humans and whether animal research 
findings are an adequate measure to draw conclusions for risks of human 
exposure,56 the effect of various exposure routes and routes of administration, 
possible unintended effects on non-target areas given the ability of 
nanoparticles to cross the blood-brain barrier, possible long-term effects of 
nanoparticles introduced to the human body,57 and potential interaction of 
various nanoparticles and nanomaterials within the human body.58  Struggles to 
develop mechanisms to identify, quantify, and assess the health and 
environmental impacts of nanotechnology are not confined to the United 
States; this is a global challenge.59  While developing and developed countries 
alike are channeling funding into nanotechnology research and development, 
resulting in a vast spectrum of consumer products entering the market, the 
scientific and regulatory questions abound.  The U.S. government, through the 
NNI, is currently funding targeted research studies within core research 
institutes and agencies on a number of environmental and public health and 
safety implications.60  It is also, however, spending over ninety-three percent 
of its current budget on development and support of nanotechnology 
applications.61 
As nanotechnology advances, particularly in the realm of medicine and 
human health, ample attention to scientific developments in characterizations 
and assessment, adverse event reporting specific to nanocharacteristics, and 
post-market surveillance are necessary to investigate and respond to the effects 
of these products on the public.  Several key federal agencies, including the 
FDA, the Environmental Protection Agency (“EPA”), and the Occupational 
Safety and Health Administration, are situated to play a large part in 
generating, tracking, and disseminating this information.  Part II provides an 
 
 56. See David B. Resnik & Sally S. Tinkle, Ethical Issues in Clinical Trials Involving 
Nanomedicine, 28 CONTEMP. CLINICAL TRIALS 433, 434–37 (2007) (noting limitations of animal 
experimentation in discerning long-term effects and differing reactivity between animals and 
humans). 
 57. Bawa & Johnson, supra note 46, at 885. 
 58. Christian Lenk & Nikola Biller-Andorno, Nanomedicine—Emerging or Re-Emerging 
Ethical Issues? A Discussion of Four Ethical Themes, 10 MED. HEALTH CARE & PHIL. 173, 176 
(2007). 
 59. See infra Part III.A. 
 60. See, e.g., SUBCOMM. ON NANOSCALE SCI., ENG’G, & TECH., NAT’L SCI. & TECH. 
COUNCIL, NATIONAL NANOTECHNOLOGY INITIATIVE STRATEGIC PLAN 29–30 (2011), available 
at http://www.nano.gov/nnistrategicplan211.pdf. 
 61. This is based on the NNI’s 2011 budget of a total of $1.76 billion, with $117 million for 
environmental, health, and safety research. SUBCOMM. ON NANOSCALE SCI., ENG’G, & TECH., 
NAT’L SCI. & TECH. COUNCIL, THE NATIONAL NANOTECHNOLOGY INITIATIVE: RESEARCH AND 
DEVELOPMENT LEADING TO A REVOLUTION IN TECHNOLOGY AND INDUSTRY, SUPPLEMENT TO 
THE PRESIDENT’S 2011 BUDGET 11 (2010), available at http://nano.gov/sites/default/files/pub_re 
source/nni_2011_budget_supplement.pdf. 
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overview of the FDA’s oversight of drugs, medical devices, and biologics, 
highlighting the abbreviated approval pathways to market and in particular the 
biosimilar pathway introduced in the ACA, and the mechanisms of overseeing 
products that combine aspects of these three product areas. 
II.  TRADITIONAL FOOD AND DRUG ADMINISTRATION OVERSIGHT 
FRAMEWORKS FOR MEDICAL AND HEALTH CARE PRODUCTS 
One of eleven agencies within the Department of Health and Human 
Services (“DHHS”), the FDA is tasked with enforcing a broad range of federal 
statutes with products accounting for a quarter of all consumer spending in the 
United States, including eighty percent of the national food supply and all 
human drugs, medical devices, cosmetics, vaccines, tissues for 
transplantations, and radiation-emitting products.62  In addition to overseeing 
products, the FDA is also “responsible for advancing the public health by 
helping to speed innovations that make medicines more effective, safer, and 
more affordable and by helping the public get the accurate, science-based 
information they need to use medicines and foods to . . . improve their 
health.”63  Recent legislation also provides both increased authority over 
tobacco products64 and a new approval pathway for follow-on biologics65 that 
further enlarges the FDA docket. 
The FDCA delineates three product categories applicable to nanomedicine: 
drugs, medical devices, and biologics.66  These are the three most heavily 
regulated consumer products throughout the pre- and post-marketing phases 
 
 62. Regulatory Information: Legislation, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/ 
RegulatoryInformation/Legislation/default.htm (last updated May 4, 2011);  Press Release, U.S. 
Food & Drug Admin., The Food and Drug Administration Celebrates 100 Years of Service to the 
Nation (Jan. 4, 2006), available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce 
ments/2006/ucm108572.htm. 
 63. What We Do, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/AboutFDA/WhatWeDo/ 
default.htm (last visited Jan. 22, 2012). 
 64. Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, 123 Stat. 
1776, 1776–1852 (2009) (codified in scattered sections of the U.S. Code). 
 65. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, § 7002, 124 Stat. 119, 
804–821 (2010) (codified at 42 U.S.C. § 262 (Supp. IV 2010) & 21 U.S.C. § 355(a) (Supp. IV 
2010)).  The biosimilars provisions are found in Title VII: Biologics Price Competition and 
Innovation.  The new follow-on biologics provisions create statutory mechanisms to provide for 
approval of a biological product that is “biosimilar” and/or “interchangeable” with a biologic 
reference product already on the market.  This status is to be based on whether a follow-on 
product is “highly similar” to the reference product.  Id.  A biologic is defined as “a virus, 
therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic 
product, or analogous product, or arsphenamine or derivative of arsphenamine (or any other 
trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease 
or condition of human beings.”  42 U.S.C. § 262(i) (2006). 
 66. See infra Part II.A–C. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
2012] REASSESSING SAFETY FOR NANOTECHNOLOGY COMBINATION PRODUCTS 479 
with substantial data requirements and a spectrum of compliance and 
enforcement mechanisms in the FDA’s arsenal.  However, the extent of 
regulation varies according to a multitude of factors, including whether a drug 
is a new drug or a generic drug, whether a medical device must go through the 
premarket approval process or is substantially equivalent to a device already on 
the market,67 and, following the 2010 health care legislation, whether a 
biologic product is biosimilar and thus able to progress through a streamlined 
(and yet to be developed) approval process.68  A broad overview of the 
pathway to market for drugs, medical devices, and biologics is below. 
A. Human Drugs 
Oversight of both human drugs and medical devices is set out in the 
FDCA.69  The new drug application (“NDA”) process involves the most 
rigorous review of any FDA-regulated product and is overseen by the CDER.70  
It can take upwards of sixteen years and cost over a billion dollars to bring a 
new drug to market.71  The touchstone measures of this process are ultimately 
safety and efficacy but oversight by the FDA spans identification, synthesis, 
and purification of an active pharmacological ingredient; pre-clinical and 
animal testing; clinical trials; manufacturing processes; review of the product 
for final approval; and post-market performance.72  New human drugs73 must 
 
 67. An extended discussion of the FDA drug and medical device review, approval, and 
clearance processes are outside the scope of this article.  They are addressed extensively 
elsewhere in the literature. 
 68. 42 U.S.C. § 262(i)(2)–(3) (Supp. IV 2010). 
 69. Pub. L. No. 75-717, 52 Stat. 1040 (codified as amended in scattered sections of 21 
U.S.C.). 
 70. About the Center for Drug Evaluation and Research, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ 
default.htm (last visited Jan. 22, 2012). 
 71. Chris L. Waller et al., Strategies to Support Drug Discovery Through Integration of 
Systems and Data, 12 DRUG DISCOVERY TODAY 634, 634 (2007). 
 72. 21 U.S.C. § 355 (2006). 
 73. A drug is defined as: 
(A) articles recognized in the official United States Pharmacopeia . . . ; and (B) articles 
intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in 
man or other animals; and (C) articles (other than food) intended to affect the structure or 
any function of the body of man or other animals; and (D) articles intended for use as a 
component of any articles specified in clause (A), (B), or (C). 
Id. § 321(g)(1).  A new drug is defined as: 
(1) Any drug (except a new animal drug or an animal feed bearing or containing a new 
animal drug) the composition of which is such that such drug is not generally recognized, 
among experts qualified by scientific training and experience to evaluate the safety and 
effectiveness of drugs, as safe and effective for use under the conditions prescribed, 
recommended, or suggested in the labeling. 
Id. § 321(p)(1). 
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satisfy safety, efficacy, and manufacturing standards, among other substantive 
requirements.74  Applicants must progress through key stages in the approval 
process including an investigational new drug application (“IND”) based on 
animal studies and three core stages of clinical trials, culminating in an NDA.75  
The FDA also maintains significant post-market authority over approved drug 
products as a result of 2007 amendments.76 
Under the NDA umbrella, there are three routes for drugs to enter the 
market faster where they are intended to treat serious or life-threatening 
diseases: priority review, fast track, and accelerated approval.77  These have 
been established either by agency policy, regulation, or statute.78  Each route is 
distinct, but they share the underlying goal of speeding up the availability of 
the drug based on its treatment promise.79  Priority review is a designation 
given to new drug applications by FDA reviewers in order to speed up the time 
of review by a few months for drugs that appear to offer major advances in 
treatment or will provide treatment where there is currently no adequate 
therapy.80 
 
 74. Id. § 355. 
 75. Details of the NDA process are detailed elsewhere.  Following FDA approval of an 
Investigational New Drug (“IND”) application, clinical trials involve three key phases.  Phase I 
studies are conducted on healthy subjects for basic metabolism, pharmacology and initial safety 
and dosage measures.  Phase II studies are larger scale (several hundred people) and collect initial 
measures of effectiveness and continues safety, toxicology, and dosage measures.  The sponsor 
meets with the FDA at the end of Phase II in order to continue into Phase III, which enroll up to 
several thousand subjects for large-scale safety and efficacy measures, and specifically to identify 
rare adverse events in a larger population.  The FDA’s Drug Review Process: Ensuring Drugs Are 
Safe and Effective, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/ResourcesForYou/ 
Consumers/ucm143534.htm (last visited Jan. 22, 2012). 
 76. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, 121 Stat. 
823 (codified as amended in scattered sections of 21 U.S.C.).  The Food and Drug Administration 
Amendments Act (“FDAAA”), among other provisions, expanded the scope of clinical trial 
registration and post-market surveillance in response to growing concerns about public 
availability of trial information and is viewed as a strong step forward in efforts to increase 
transparency.  Many question the utility of the information in the face of limited public 
understanding and ability to interpret results and urge more efforts to promote public 
understanding of clinical trial information that is put into the public domain.  See, e.g., Deborah 
A. Zarin & Tony Tse, Moving Toward Transparency of Clinical Trials, 319 SCI. 1340, 1342 
(2008). 
 77. Fast Track, Accelerated Approval and Priority Review, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnew
therapies/ucm128291.htm (last visited Jan. 22, 2012) [hereinafter Fast Track]. 
 78. Id. 
 79. Id. 
 80. This designation and process is established in agency policy and effectively sets the goal 
for time of review at six months rather than ten months for standard review.  Id.  For examples of 
agency policy regarding expedited drug approval, see CTR. FOR DRUG EVALUATION AND 
RESEARCH, U.S. FOOD & DRUG ADMIN., MANUAL OF POLICIES AND PROCEDURES 6020.3: 
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Fast Track is defined by the FDA as “a process designed to facilitate the 
development, and expedite the review of drugs to treat serious diseases and fill 
an unmet medical need.”81  The FDA considers factors such as the impact on 
day-to-day functions and survival or the likelihood that, if left untreated, the 
disease will become more serious in order to determine whether it is serious or 
life-threatening.82  Where no treatments exist, this is clearly an “unmet need”; 
where therapies do currently exist, the drug must show that it performs some 
advantage over that existing product.83  This approval process typically 
requires post-approval studies and the progress of these studies, as well as the 
plan for completion or termination and any reasons for delay, must be 
described in the annual report to the FDA.84  The FDA may also waive the 
IND application requirement and may accept a continuous application during 
the Fast Track process, where portions of the NDA may be submitted before a 
full NDA is prepared, allowing frequent feedback and interactions throughout 
the development process.85 
Accelerated review allows the earlier approval of drugs that are intended to 
treat serious diseases or life-threatening diseases and fill an unmet medical 
need based on a surrogate endpoint rather than a traditional clinical trial 
outcome measure.86  The FDA may also impose post-market studies as part of 
the accelerated approval, tasking the drug sponsor to “study the drug further, to 
verify and describe its clinical benefit, where there is uncertainty as to the 
relation of the surrogate endpoint to clinical benefit, or of the observed clinical 
benefit to ultimate outcome.”87  The regulations provide circumstances under 
which the FDA may withdraw the approved drug from the market, subject to 
 
REVIEW OF CLASSIFICATION POLICY: PRIORITY (P) AND STANDARD (S) (2007); SOPP 8405: 
Complete Review and Issuance of Action Letters, U.S. FOOD & DRUG ADMIN., http://www.fda. 
gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ProceduresSOPPs/ 
ucm073481.htm (last visited Jan. 22, 2012). 
 81. Fast Track, supra note 77.  This process was established by statute.  21 U.S.C. § 356(a) 
(2006). 
 82. Fast Track, supra note 77. 
 83. Id. 
 84. 21 U.S.C. § 356(b) (outlining the requirements for the reports of post-marketing studies).  
This provision requires that the company’s annual report identify each Phase IV commitment 
(post-market studies) for the approved product, describe the progress being made, and indicate the 
plan for completion or termination.  Id. 
 85. See Fast Track, supra note 77. 
 86. This process was established by regulation.  21 C.F.R. §§ 314.500–560, 601.40–601.46 
(2010).  Surrogate endpoints are physiological assessments recognized as validated indicators of 
clinical benefit (i.e., a biomarker).  Id. § 314.510.  Examples include reduced blood pressure for 
anti-hypertensives, reduced fractures for osteoporosis, and reduced cholesterol levels for lipid-
altering drugs. 
 87. Id. § 314.510. 
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notice and a hearing.  These include failure to verify clinical benefit and failure 
to perform a required post-market study with due diligence.88 
Increasing concern about the failure to assure that industry fulfill post-
approval commitments led to the Food and Drug Administration Amendments 
Act of 2007 (“FDAAA”).89  Pre-2007, the FDA relied on two statutory 
provisions broadly dealing with maintenance of records and reports as the basis 
for requests for post-approval nonclinical or clinical studies (aside from those 
required under the accelerated approval regulations).90  With enactment of 
FDAAA, the authority of the FDA to require post-approval studies has been 
explicitly provided; the FDA can now rely on new provisions to require further 
studies for safety and efficacy, along with increased authority to review these 
commitments.91  Risk evaluation and mitigation strategies (“REMS”) come in 
many forms: they can require a Medication Guide for patients, prescription 
physician information, implementation plans, communications to health care 
providers and pharmacies, and various limitations on labeling, promotion, and 
prescribing to assure safe use.92  These amendments provide significant 
enforcement mechanisms for violations, which are deemed to be misbranding 
and carry additional civil money penalties for violations.93  The FDAAA also 
provides additional requirements for the industry regarding the entry of clinical 
trial information into existing clinical online databases and creation of new 
online reporting resources for adverse events as a means to bolster 
transparency to the public.94 
However, problems with industry adherence to post-market requirements 
linger.  In September 2009, the U.S. Government Accountability Office 
(“GAO”) issued a report addressing perceived problems with the FDA’s 
accelerated approval program.95  The report details that while the FDA 
approved ninety drug applications based on surrogate endpoints between 1992 
and November 2008, only two-thirds of the required post-market studies have 
been fulfilled and deemed “closed” by the FDA.96  Pointing out weakness in 
monitoring and enforcement, the GAO urged the FDA to clarify conditions for 
withdrawal if sponsors fail to complete the required studies or if the studies fail 
 
 88. Id. § 314.530. 
 89. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, 121 Stat. 
823 (codified as amended in scattered sections of 21 U.S.C.). 
 90. See 21 U.S.C. §§ 355(e), (k) (2006). 
 91. See 21 U.S.C. §§ 355(o)–(p), 355-1 (Supp. IV 2010). 
 92. Id. § 355-1. 
 93. Id. § 352(y)–(z); Id. § 333(f)(4). 
 94. Id. § 355(k). 
 95. U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-090-866, NEW DRUG APPROVAL: FDA 
NEEDS TO ENHANCE ITS OVERSIGHT OF DRUGS APPROVED ON THE BASIS OF SURROGATE 
ENDPOINTS (2009) [hereinafter FDA NEEDS TO ENHANCE ITS OVERSIGHT]. 
 96. Id. at 14. 
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to demonstrate the drug’s clinical effectiveness.97  Likely as a result of this 
report critical of the FDA’s handling of these products, the FDA recently 
asserted this withdrawal authority for the first time, notifying Shire 
Pharmaceuticals and generic manufacturers of the Agency’s proposal to 
withdraw ProAmatine (and the generic midodrine) from the market based on a 
lack of required post-marketing data confirming the clinical benefit of the 
drug.98  The FDA has since opened a public docket on the matter.99 
A drug sponsor may also apply for changes to a drug approval utilizing a 
supplemental NDA (“sNDA”)100 where an approved application exists that 
underwent a full premarket approval process and the sponsor wishes to make 
changes to that marketed drug.101  These are termed “prior approval” 
supplements and FDA approval is required before changes are implemented.102  
Only major changes require a sNDA: changes to the drug or the manufacturing 
process, facilities, or equipment that have “a substantial potential to have an 
adverse effect on the identity, strength, quality, purity, or potency of the drug 
product as these factors may relate to the safety or effectiveness of the drug 
product.”103  These are typically changes to the active ingredient or active 
product, including major labeling changes such as a new indication or new 
dosing and major manufacturing changes such as formulation or synthesis 
changes.104 
The generic drug approval process, termed the abbreviated new drug 
application (“ANDA”), was implemented in 1984 with the Hatch-Waxman 
Act.105  The ANDA process combines patent term extension and data 
exclusivity provisions with authorization for the FDA to approve generic 
versions of already-approved pioneer drugs.106  These provisions were 
applicable only to conventional small molecule drugs and did not include 
 
 97. Id. at 36. 
 98. Midodrine Update, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/DrugSafety/ 
ucm225444.htm (last visited Jan. 22, 2012). 
 99. Id.; see also Trials to Verify and Describe Clinical Benefit of Miodrine Hydrochloride; 
Establishment of Public Docket, 76 Fed. Reg. 1620 (Jan. 11, 2011). 
 100. 21 U.S.C. § 356a(c)(1) (2006). 
 101. 21 C.F.R. § 314.70 (2010). 
 102. CTR. FOR DRUG EVALUATION AND RESEARCH, U.S. FOOD & DRUG ADMIN., GUIDANCE 
FOR INDUSTRY: CHANGES TO AN APPROVED NDA OR ANDA 3 (2004), available at 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ 
UCM077097.pdf [hereinafter CHANGES TO AN APPROVED NDA OR ANDA]. 
 103. 21 C.F.R. § 314.70(b)(1) (2010). 
 104. CHANGES TO AN APPROVED NDA OR ANDA, supra note 102, at 12–13. 
 105. The Drug Price Competition and Patent Term Restoration Act of 1984 (also known as 
the Hatch-Waxman Act) established the abbreviated new drug application process at 21 U.S.C. § 
355(j) (2006).  Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-
417, sec. 101, 98 Stat. 1585, 1585–92 (codified at 21 U.S.C. § 355(j) (2006)). 
 106. 21 U.S.C. § 355(j). 
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biologics, which are regulated under the rubric of the Public Health Services 
Act.107  An ANDA does not generally require preclinical and clinical data to 
establish safety and efficacy but must demonstrate that the product is 
“bioequivalent” and performs in the same manner as the pioneer drug in terms 
of active ingredient, dosage and route of administration, and strength and 
conditions of use.108  A showing of bioequivalence requires “the absence of a 
significant difference in the rate and extent to which the active ingredient or 
active moiety in pharmaceutical equivalents or pharmaceutical alternatives 
becomes available at the site of drug action when administered at the same 
molar dose under similar conditions in an appropriately designed study.”109  
The FDA may approve an ANDA for a generic version of a pioneer drug after 
all relevant patents have expired for the pioneer drug and all relevant periods 
of market exclusivity for the pioneer drug have also expired.110  The Orange 
Book is the key resource to guide the ANDA applicant and includes patent 
listings and information on generic drug approvals and the corresponding 
pioneer drug.111  State substitution laws allow pharmacists to dispense the 
generic (i.e., therapeutic equivalent) drug when a physician prescribes the 
pioneer, except if explicitly directed otherwise by physician.112 
Nanodrugs are currently being evaluated by the FDA via the NDA process.  
However, a number of them have benefited from accelerated approval because 
of their application in treatments for serious or life-threatening illnesses.113 The 
GAO report’s Appendix I lists the drugs approved under the accelerated 
approval process during the 1992 to November 2008 time period, including the 
 
 107. Jordan Paradise, The Devil is in the Details: Health-Care Reform, Biosimilars, and 
Implementation Challenges for the Food and Drug Administration, 51 JURIMETRICS J. 279, 282 
(2011). 
 108. 21 U.S.C. § 355(j)(2)(A)(ii)–(iii). 
 109. 21 C.F.R. § 320.1(e) (2010).  Bioavailability is defined as “the rate and extent to which 
the active ingredient or active moiety is absorbed from a drug product and becomes available at 
the site of [drug] action.”  Id. § 320.1(a).  The drug product is defined as the “finished dosage 
form . . . that contains the active drug ingredient, generally, but not necessarily, in association 
with inactive ingredients.”  Id. § 320.1(b).  Pharmaceutical equivalents are defined as drug 
products “that contain identical amounts of the identical active drug ingredient.”  Id. § 320.1(c).  
And pharmaceutical alternatives are defined as “drug products that contain the identical 
therapeutic moiety, or its precursor, but not necessarily in the same amount or dosage form.”  Id. 
§ 320.1(d). 
 110. 21 U.S.C. § 355(j)(5)(A)–(E). 
 111. CTR. FOR DRUG EVALUATION & RESEARCH, U.S. FOOD & DRUG ADMIN., APPROVED 
DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS (THE ORANGE BOOK) (31st 
ed. 2011), available at http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ 
UCM071436.pdf.  The Orange Book lists patent and exclusivity information for pioneer and 
generic drugs.  The searchable electronic version is available at http://www.accessdata.fda.gov/ 
scripts/cder/ob/default.cfm. 
 112. Jesse C. Vivian, Generic-Substitution Laws, U.S. PHARMACIST, June 2008, at 30, 32–33. 
 113. See infra Figure 1. 
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drugs Doxil (approved both for treatment of Kaposi’s sarcoma in specific 
patients with Acquired Immunodeficiency Syndrome and for treatment of 
metastatic carcinoma of the ovary in specific patients) and DepoCyt (approved 
for treatment of lymphmatous meningitis).114  Both drugs utilize 
nanotechnology.115  As companies with existing NDAs for nanotechnology-
based drugs pursue additional indications, dosages, and patient populations, 
many will utilize the sNDA route to achieve this.  For example, Abraxis 
Biosciences reported in early 2010 that it was near completion of Phase 3 
clinical trials for a second indication of Abraxane (active ingredient paclitaxel) 
originally approved in 2005, which the company projected would be the 
subject of an sNDA sometime in 2011.116  Ortho Biotech has also utilized the 
sNDA process for several subsequent new or modified indications of Doxil 
(active ingredient doxorubicin hydrochloride), as well as labeling changes.117 
B. Medical Devices 
Medical devices118 are subject to a tiered classification system based on 
perceived level of risk.  Most medical devices considered low and medium risk 
can be marketed with merely a premarket notification to the FDA if 
“substantially equivalent” to an already marketed device or may be exempt 
from premarket notification altogether; higher-risk Class II or Class III devices 
that are not substantially equivalent must go through a pre-market process 
 
 114. Both drugs were approved using response rate as the surrogate endpoint.  See FDA 
NEEDS TO ENHANCE ITS OVERSIGHT, supra note 95, at 42, 44 tbl.5. 
 115. Paradise et al., supra note 14, at 411–12; see infra Figure 1. 
 116. Press Release, Abraxis Bioscience, Abraxane Meets Primary Endpoint in Phase 3 Trial 
for Advanced Non-Small Cell Lung Cancer, (Mar. 17, 2010), available at http://www.nanotech-
now.com/news.cgi?story_id=37282 (last visited Aug. 8, 2011).  Celgene acquired Abraxis 
Biosciences in June 2010.  Andrew Pollack, Prominent Drug Chief to Sell Abraxis BioScience to 
Celgene for $2.9 Billion, N.Y. TIMES, July 1, 2010, at B3. 
 117. Doxil Label and Approval History, U.S. FOOD & DRUG ADMIN., http://www.access 
data.fda.gov/scripts/cder/drugsatfda/index.cfm (search the drug name “Doxil”; then follow “Label 
Information” hyperlink) (last visited Jan. 22, 2012). 
 118. A medical device: 
means an instrument, apparatus, any component, implement, machine, contrivance, 
implant, in vitro reagent, or other similar or related article, including any component part, 
or accessory which is – 
(1) recognized for use in the official National Formulary, or . . . , 
(2) intended for use in the diagnosis of disease or other conditions, or in the cure, 
mitigation, treatment, or prevention of disease, in man or other animals, or 
(3) intended to affect the structure or any function of the body of man or other animals, 
and 
which does not achieve its primary intended purposes through chemical action within or 
on the body of man or other animals and which is not dependent upon being metabolized 
for the achievement of its primary intended purposes. 
21 U.S.C. § 321(h) (2006). 
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demonstrating safety and efficacy as set forth in regulations.119  The Center for 
Devices and Radiological Health (“CDRH”) oversees medical devices.120 
Class III is the highest risk classification for medical devices, requiring a 
pre-market approval (“PMA”) filing prior to marketing in the United States 
unless it is a product amenable to the 510(k) clearance process based on 
classification listings and “substantial equivalence,” described below.121  Class 
III PMA devices are those that are life-sustaining and life-supporting.122  
Similar to an NDA for a new drug, the PMA must list uses and indications of 
the specific product, warning and contraindications, product labeling, results of 
clinical trials gathered following approval of an investigational device 
exemption (comparable to an IND for a new drug), and information regarding 
manufacturing processes.123  Examples of high-risk Class III products subject 
to the PMA process include heart valves, implantable cardioverter 
defibrillators, and pacemakers.124  Clinical studies for a Class III medical 
device can take four to five years and cost fifteen to twenty million dollars.125 
Premarket notification is required for most Class II and III devices, which 
is termed a 510(k) clearance in reference to the FDCA section that establishes 
the process.126  These devices pose an increased, moderate level of risk.127  
This process does not mandate a drug-like clinical trial and PMA process as is 
required for Class III highest risk devices.  Rather, it requires a submission that 
 
 119. 21 U.S.C. § 360(c). 
 120. About the Center for Devices and Radiological Health, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/de 
fault.htm (last visited Jan. 22, 2012). 
 121. The established 510(k) classifications for device manufacturers are listed in 21 C.F.R. §§ 
862–880 (2010).  If a new device has the same intended use and meets the general description of 
the device in the classification, then the new device will fall under that regulation scheme.  If the 
device is not currently listed, it will be considered a Class III device and subject to premarket 
approval requirements until the FDA determines otherwise. 
 122. Edward C. Wilson, Jr. & Laurie A. Clarke, The Medical Device Approval Process, in A 
PRACTICAL GUIDE TO FOOD AND DRUG LAW AND REGULATION 127, 129 (Kenneth R. Piña & 
Wayne L. Pines, eds., 2d ed. 2002).  These products must typically first complete clinical testing 
under an investigational device exemption (“IDE”), which is similar in content and requirements 
to the drug IND but generally involves fewer participants and less extensive clinical trials.  Jordan 
Paradise et al., Evaluating Oversight of Human Drugs and Medical Devices: A Case Study of the 
FDA and Implications for Nanobiotechnology, 37 J.L. MED. & ETHICS 598, 602 (2009). 
 123. 21 U.S.C. § 360e(c) (2006). 
 124. See Alan M. Garber, Modernizing Device Regulation, 362 NEW ENG. J. MED. 1161 
(2010). 
 125. Andrew S. Baluch, Angstrom Medica: Securing FDA Approval and Commercializing a 
Nanomedical Device, 2  NANOTECHNOLOGY L. & BUS. 168, 172 (2005). 
 126. 21 U.S.C. § 360(k) is also expressed as Food, Drug, and Cosmetic Act § 510(k).  Some 
Class II devices are exempt as classified in the Federal Register.  See 21 C.F.R. §§ 862–892 
(2010). 
 127. 21 U.S.C. § 360(k). 
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a device is “substantially equivalent” to a device already on the market and 
provides for special controls,128 which include performance standards, post-
market surveillance, patient registries, development of guidelines, 
recommendations and other actions deemed appropriate by the FDA to 
“provide reasonable assurance of safety and effectiveness.”129  Substantial 
equivalence is defined as either: (1) having the same intended use and the same 
technological characteristics of an existing device; or (2) having the same 
intended use and different technological characteristics but the information 
submitted to the FDA does not raise new questions of safety and efficacy and 
demonstrates that the device is at least as safe as the legally manufactured 
device.130  Review times are approximately three months for a 510(k) 
submission and eight and a half months for a Class III PMA device.131  
Reportedly, of the first six nano-medical devices to enter the market, none 
were approved through the PMA approval process but instead the 510(k) 
process based on substantial equivalence to an existing device.132  The FDA 
website reveals that the overwhelming majority of medical devices utilizing 
the term “nano” (and appropriately described as operating or containing 
materials at the nanoscale) have been cleared through the 510(k) process.133 
Finally, Class I devices are the lowest level of risk, subject typically to 
general controls which consist of facility registration and product listing with 
the FDA, record maintenance and filing of marketing reports, adherence to 
good manufacturing procedures (“GMPs”) and quality system registrations 
(“QSRs”), and any distribution and use limitations imposed by the FDA.134  
All devices (Class I–III) are subject to these general controls; additional 
controls are added as the perceived level of risk increases.  All Class I devices 
undergo either the 510(k) process or are exempt from premarket notification 
entirely via FDA policy or regulation.135 
A recent IOM report revealed that a staggering ninety-nine percent of 
medical devices enter the market either through the 510(k) process or are 
 
 128. Id. § 360c(a)(1)(B). 
 129. Id. 
 130. Id. § 360c(i)(1)(A). 
 131. Elizabeth Mansfield et al., Food and Drug Administration Regulation of in Vitro 
Diagnostic Devices, 7 J. MOLECULAR DIAGNOSTICS 2, 3 (2005). 
 132. Gary E. Marchant et al., International Harmonization of Regulation of Nanomedicine, 3 
STUD. ON ETHICS L. & TECH art. 6, at 3–4 (2009), http://www.bepress.com.ezp.slu.edu/cgi/view 
content.cgi?article=1120&context=selt. 
 133. The FDA website has a searchable link for 510(k) and PMA medical devices, arranged 
by year.  For the 510(k) search, visit http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/ 
pmn.cfm (last updated Jan. 5, 2012).  For the PMA search, visit http://www.accessdata.fda.gov/ 
scripts/cdrh/cfdocs/cfPMA/pma.cfm (last updated Jan. 5, 2012).  See also infra Figure 2. 
 134. 21 U.S.C. § 360c(a)(1)(A) (2006). 
 135. PETER BARTON HUTT ET AL., FOOD AND DRUG LAW 992 (3d ed. 2007). 
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exempt from any premarket review each year.136  The Director of the CDRH 
indicates that this amounts to approximately 3,000 products passing through 
the 510(k) process each year.137  In response to ongoing criticism and Congress 
tasking the IOM with a critique of the 510(k) system,138 the CDRH has 
conducted internal investigations of the 510(k) process.  The CDRH released 
two preliminary reports in August 2010 assessing: (1) the existing oversight 
frameworks for 510(k) medical devices;139 and (2) the CDRH’s utilization of 
scientific information in decision-making within the Agency.140  The 510(k) 
report addresses long-standing concerns regarding the utilization of substantial 
equivalence measures rather than requiring premarket approval processes for 
assuring safety and efficacy.141  One finding highlighted within the report was 
the inconsistent interpretation of terms such as “substantial equivalence,” 
“intended use,” and “different technological characteristics” and the 
relationship of these terms to the predicate device.142  This is especially 
relevant with respect to nanotechnology, as most medical devices utilizing 
nanotechnology have been cleared via the 510(k) route.143  Undoubtedly, these 
medical devices exhibit new features, properties, and characteristics due to the 
nanoscale, raising questions about whether the FDA has appropriately allowed 
them clearance under the 510(k) process. 
The second CDRH report acknowledges the needs of the FDA in the face 
of new scientific information: the need for high-quality and up-to-date 
information on new science; the need for analytical and technical expertise to 
assess new science; and the need for operational and organizational 
 
 136. INST. OF MED., supra note 3, at 4; see also Protecting Patients from Defective Medical 
Devices: Hearing on S. 540 Before the S. Comm. on Health, Educ., Labor and Pensions, 111th 
Cong. 30 (2009) (testimony of Peter Barton Hutt, Senior Counsel, Covington & Burling LLP). 
 137. Letter from Jeffrey Shuren, Dir., U.S. Food & Drug Admin. Ctr. for Devices & 
Radiological Health, to the American Public, available at   http://www.fda.gov/downloads/About 
FDA/CentersOffices/CDRH/CDRHReports/UCM239451.pdf. 
 138. Activity Description, Public Health Effectiveness of the FDA 510(k) Clearance Process, 
INST. OF MED., http://www.iom.edu/Activities/PublicHealth/510KProcess.aspx (last updated 
Aug. 1, 2011). 
 139. CTR. FOR DEVICES AND RADIOLOGICAL HEALTH, U.S. Food & Drug Admin., 1 CDRH 
PRELIMINARY INTERNAL EVALUATIONS: 510(K) WORKING GROUP PRELIMINARY REPORT AND 
RECOMMENDATIONS (2010) [hereinafter 510(K) REPORT]. 
 140. CTR. FOR DEVICES AND RADIOLOGICAL HEALTH, U.S. Food & Drug Admin., 2 CDRH 
PRELIMINARY INTERNAL EVALUATIONS: TASK FORCE ON THE UTILIZATION OF SCIENCE IN 
REGULATORY DECISION MAKING PRELIMINARY REPORT AND RECOMMENDATIONS (2010) 
[hereinafter TASK FORCE REPORT]. 
 141. 510(K) REPORT, supra note 139. 
 142. Id. at 4–5.  Specifically, the report indicates that “[a]s the 510(k) standard has been 
applied to a wider range of devices over time, including increasingly varied, complex, and 
potentially higher-risk technologies, the need for greater clarity with respect to these terms has 
become even more pressing.”  Id. 
 143. See infra Figure 2. 
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infrastructure to support the development of expertise and information and to 
effectuate communication.144  The report defines “new science” as “new data 
about the risk/benefit profile of devices; new information about manufacturing 
practices and processes; new scientific fields and technologies, such as 
nanotechnology; and new regulatory science, including analytic, tools.”145  
Specifically, the report presents as a case study a novel technology described 
as a device under review by the CDRH that is “a first of a kind device that uses 
a new material with unique or unknown biocompatibility properties.”146  The 
report gives examples of novel technology within the report as including 
advances in nanotechnology and medical robotics.147  As questions of interest, 
the report asks what steps should be taken to assure that the novel technologies 
or novel uses are safe and effective.148  In order to set the course for future 
changes to the 510(k) process, the FDA has published an Action Plan, laying 
out twenty-five specific actions to address problems in the current process.149  
These include guidance to provide clarity on the 510(k) process, criteria for 
identifying “different questions of safety and effectiveness,” and 
“technological changes that will generally raise such questions.”150  The FDA 
also plans to establish a Center Science Council comprised of external 
scientific experts to aid in developing responses to new scientific 
information151 and “address[ing] important scientific issues regarding new 
medical device technologies.”152  The Action Plan also directs a number of 
specific questions to the IOM, including clarification of when a particular 
device can no longer be used by a 510(k) applicant as a predicate device for 
purposes of substantial equivalence.153 
On July 29, 2011, the IOM released its much-anticipated report on the state 
of the FDA’s 510(k) process.154  The report came to two core conclusions: (1) 
the “510(k) clearance process is not intended to evaluate the safety and 
effectiveness of medical devices” and “cannot be transformed into a premarket 
 
 144. TASK FORCE REPORT, supra note 140, at 3. 
 145. Id. at 39. 
 146. Id. at 45. 
 147. Id. at 13. 
 148. Id. at 45. 
 149. Plan of Action for Implementation of 510(k) and Science Recommendations, U.S. FOOD 
& DRUG ADMIN., http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHR 
eports/UCM239450.pdf (last visited Nov. 30, 2011). 
 150. Id. at 2. 
 151. Id. at 3. 
 152. Letter from Jeffrey Shuren, Dir., U.S. Food & Drug Admin. Ctr. for Devices & 
Radiological Health, to the American Public, available at http://www.fda.gov/downloads/About 
FDA/CentersOffices/CDRH/CDRHReports/UCM239451.pdf. 
 153. Plan of Action for Implementation of 510(k) and Science Recommendations, supra note 
149, at 6. 
 154. INST. OF MED., supra note 3. 
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evaluation of safety and effectiveness” as long as substantial equivalence is the 
clearance standard;155 and (2) “[i]nformation that would allow an 
understanding of the extent to which the 510(k) clearance process either 
facilitates or inhibits innovation does not exist.”156  The IOM did not address 
the specific questions raised by the FDA in their Action Plan, but considered 
them in their assessment.157  The IOM offered eight recommendations to the 
FDA, urging that any further investment in remedying the 510(k) process 
would not be prudent, in that resources would be better spent developing a new 
regulatory framework to replace it.158  These recommendations included 
collection of adequate information to guide development of such a new 
regulatory framework, implementation of a strategy to collect and assess post-
market information, review of authority in the post-market realm, development 
of continuous quality-improvement to track medical devices decisions to assist 
in addressing emerging issues, commission of an assessment of the effect of 
regulation of devices on innovation, and developing software-specific 
procedures.159 
These CDRH movements and the IOM report regarding shortcomings in 
the 510(k) process generally are extremely relevant to nanotechnology in terms 
of the uncertainty surrounding the novelty of the technologies involved, the 
lack of metrics to measure and test, and overall challenges in understanding the 
differences in scientific and technical aspects of the spectrum of medical 
devices incorporating nanotechnology.  Specifically, there are significant 
questions of whether substantial evidence is appropriate where the links 
between the technological differences and safety and efficacy may largely 
remain unknown. 
C. Biological Products 
Biologics are medical products derived from living sources (animals, 
human, and microorganisms) and include viruses, therapeutic serums, toxins 
and antitoxins, vaccines, blood and blood products, and cells, tissues and gene 
therapy products.160  While biologics are regulated similarly to drugs following 
1997 amendments to the FDCA and the Public Health Service Act 
 
 155. Id. at 193. 
 156. Id. at 195. 
 157. Id. at xi–xii. 
 158. Id. at 7–8. 
 159. INST. OF MED., supra note 3, at 7–13. 
 160. A biological product is defined as “virus, therapeutic serum, toxin, antitoxin, vaccine, 
blood, blood component or derivative, allergenic product, protein (except any chemically 
synthesized polypeptide) or analogous product, or arsphenamine or derivative of arsphenamine 
(or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure 
of a disease or condition of human beings.” 42 U.S.C. § 262(i) (Supp. IV 2010). 
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(“PHSA”),161 there are several important differences between the two.  Aside 
from their derivation from living sources rather than being chemically 
synthesized, biologics differ from traditional small molecule drugs in a number 
of ways—they are more complex macromolecular entities, they are typically 
manufactured using more sophisticated techniques, and they are more 
susceptible to variations in final product due to manufacturing processes, 
storage conditions, and interactions with the human body.162  The Center for 
Biologics Evaluation and Research (“CBER”) and the CDER jointly handle 
biologics.163 
The 1902 Biologics Act164 predates the FDCA.  The core provisions for the 
biologics license process are contained in the PHSA rather than the FDCA; in 
1997 the Food and Drug Amendments and Modernization Act165 amended the 
PHSA and FDCA to create parallels in the approval processes.  A biologics 
license application (“BLA”) is issued by the FDA after finding that the product 
is safe, pure, and potent and the company assures that the manufacturing 
process and facility is adequate.166  Following the 1997 amendments, biologics 
approval incorporates classical FDCA provisions and structures of NDAs, 
including good manufacturing practice requirements, INDs, post-market 
authority, and enforcement mechanisms.167  Biologics are regulated by both the 
CDER and CBER and the ultimate approval pathway (BLA or NDA) depends 
on the type of product.168  However, these amendments did not include 
incorporation of any generic approval process or patent and market exclusivity 
provisions for biologics similar to those created by the Hatch-Waxman Act for 
drugs. 
The ongoing struggle for legislative reform to the U.S, health care system 
culminated in the March 23, 2010, enactment of the ACA169 and the partner 
Health Care and Education Reconciliation Act of 2010, signed into law on 
 
 161. See 42 U.S.C. § 262(a) & note (2006) (Amendments). 
 162. Paradise, supra note 107, at 281. 
 163. Transfer of Therapeutic Products to the Center for Drug Evaluation and Research, U.S. 
FOOD & DRUG ADMIN., http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalPro 
ductsandTobacco/CBER/ucm133463.htm (last visited Jan. 22, 2012) [hereinafter Transfer of 
Therapeutic Products]. 
 164. Biologics Control Act of 1902, Pub. L. No. 57-244, 32 Stat. 728. 
 165. Food and Drug Amendments and Modernization Act, Pub. L. No. 105-115, 111 Stat. 
2296 (1997). 
 166. 42 U.S.C. § 262(a)(2); 21 C.F.R. § 601.2(a) (2010). 
 167. 42 U.S.C. § 262. 
 168. The CDER oversees the following products: monoclonal antibodies for in vivo use, 
proteins for therapeutic use extracted from animals or micro-organisms (except clotting factors), 
growth factors and enzymes, and non-vaccine therapeutic immunotherapies.  CBER oversees 
allergenics, cellular products, tissue products, gene therapy products, vaccines, and blood & 
blood products.  Transfer of Therapeutic Products, supra note 163. 
 169. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119 (2010). 
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March 30, 2010.170  In addition to extensive provisions aimed at revamping 
health insurance, the ACA includes a Biologics Price Competition and 
Innovation subtitle, authorizing the FDA to implement a regulatory approval 
process for follow-on biologics (also known as biosimilars).171  The impetus to 
develop a pathway for biologics akin to the generic drug process was largely 
the promise of cost savings.172  The generic drug industry estimates they have 
saved the U.S. health care system approximately $734 billion,173 with the first 
generic to enter the market generally offering a price twenty-five percent lower 
than the pioneer.174  This rises to eighty percent with multiple generics on the 
market.175  Biologics, on the other hand, cost an average of twenty-two times 
that of ordinary drugs,176 with the eight top selling biologics in 2008 totaling 
over $55.6 billion in sales.177  In 2008, twenty-eight percent of the 
pharmaceutical industry’s top 100 products came from biologics; projected to 
be fifty percent by 2014.178  In 2007, Americans spent $40.3 billion on biologic 
drugs (out of a total $286.5 billion for prescription drugs).179  These prices 
result in costs to individual patients.  For example, Remicade, a treatment for 
Rheumatoid arthritis, costs $20,000 per year;180 Herceptin, for treatment of 
breast cancer, costs $48,000 per year;181 Humira, for treatment of Rheumatoid 
arthritis or Crohn’s disease, costs $50,000 per year;182 and Cerezyme, for 
treatment of Gaucher disease, costs $200,000 per year.183 
The ACA’s Title VII, Subtitle A, § 7001–7003, amends the PHSA and the 
FDCA to create an approval pathway for submission of a product that is 
 
 170. Health Care and Education Reconciliation Act, Pub. L. No. 111-152, 124 Stat. 1029 
(2010). 
 171. Patient Protection and Affordable Care Act §§ 7001–03, 124 Stat. at 804–21. 
 172. Steven Kozlowski et al., Developing The Nation’s Biosimilars Program, 365 NEW ENG. 
J. MED. 385, 385 (2011). 
 173. Anthony D. So & Samuel L. Katz, Op-Ed., Biologics Boondoggle, N.Y. TIMES, Mar. 8, 
2010, at A23. 
 174. U.S. FED. TRADE COMM’N, EMERGING HEALTH CARE ISSUES: FOLLOW-ON BIOLOGIC 
DRUG COMPETITION 12 (2009). 
 175. Id. 
 176. So & Katz, supra note 173. 
 177. These biologics were Avastin ($9.2 billion), Enbrel ($8.0 billion), Remicade ($7.9 
billion), Humira ($7.3 billion), Rituxan ($7.3 billion), Herceptin ($5.7 billion), Lantus ($5.1 
billion), and Epogen/Procrit ($5.1 billion).  U.S. FED. TRADE COMM’N, supra note 174, at 5  
fig.1-1. 
 178. So & Katz, supra note 173. 
 179. FED. TRADE COMM’N, supra note 174, at 3. 
 180. Id. 
 181. Id. 
 182. So & Katz, supra note 173. 
 183. Id. 
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“biosimilar”184 and possibly “interchangeable”185 with an already-approved 
biologic.  The legislation enables the Secretary of the DHHS to issue guidance 
regarding relevant standards and criteria and to implement an approval 
processes utilizing public comment.186  The DHHS Secretary delegates this 
authority to the Commissioner of the FDA.187  The amendments give much 
discretion to the Secretary, and thus the FDA, to determine when clinical 
studies may not be necessary for a given submission.188  It also includes 
incentives to encourage development of biosimilar products.  The amendments 
create twelve years of exclusivity for pioneer biosimilar products,189 a one-year 
period of exclusivity for the first interchangeable product,190 and an additional 
six months of exclusivity for pediatric studies.191  There are also detailed patent 
disclosure and litigation provisions.192 
Topics currently under consideration by the FDA as they determine how to 
implement the new provisions include scientific and regulatory distinctions 
between the established generic drug approval processes and the new approval 
process for follow-on biologics (focusing on differences between traditional 
drugs and biologics based on size, characteristics, complexity, manufacturing 
processes, reproducibility, and concepts of similarity and interchangeability) 
and data, market, and patent exclusivity concerns.193  It remains to be seen how 
 
 184. Biosimilarity means that “the biological product is highly similar to the reference 
product notwithstanding minor difference in clinically inactive components” and there are “no 
clinically meaningful differences between the biological product and the reference product in 
terms of safety, purity, and potency.”  42 U.S.C. § 262(i)(2) (Supp. IV 2010).  The biosimilar 
must “utilize the same mechanism or mechanisms of action for the condition or conditions of 
use” that have been previously approved for the reference product; must have the same route of 
administration, dosage form, and strength; and must assure that the product is safe, pure, and 
potent.  Id. § 262(k)(2)(A)(i). 
 185. Interchangeability means that biosimilarity is fulfilled and the biologic “may be 
substituted for the reference product without the intervention of the health care provider who 
prescribed the reference product.”  Id. § 262(i)(3).  To receive interchangeable status, the 
application must include all of the information to show biosimilarity plus: a showing of the 
expectation to provide the same clinical result as reference product in any given patient; and a 
showing that where “administered more than once to an individual, the risk in terms of safety of 
diminished efficacy of alternating or switching between use of the biological product and the 
reference product is not greater than the risk of using the reference product without such 
alteration or switch.”  Id. § 262(k)(4). 
 186. Id. § 262(k)(8). 
 187. Richard M. Cooper, Introduction, in FOOD AND DRUG LAW AND REGULATION, 7 (David 
G. Adams et al. eds., 2008). 
 188. 42 U.S.C. § 262(k)(8)(A)–(B). 
 189. Id. § 262(k)(7)(A). 
 190. Id. § 262(k)(6)(A). 
 191. Id. § 262(m)(2)(A). 
 192. Id. § 262(l). 
 193. See, e.g., Kozlowski et al., supra note 172. 
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this pathway will play out.  Thus far, the FDA has formed a Biosimilar 
Implementation Committee “to plan the agency’s approach to implementing 
the statute in order to ensure that the process of evaluation, review and 
approval of products within this newly-defined product category will be 
achieved in a consistent, efficient and scientifically sound manner.”194  The 
FDA reports formation of a working group195 and the Office of New Drugs 
(“OND”) has appointed an Acting Associate Director for Biosimilars to assist 
in the coordination of the CDER’s implementation efforts.196 A biosimilars 
Review Committee has also been created within the CDER, “serv[ing] in an 
advisory capacity to the OND review divisions as they consider sponsor 
requests for advice about how to develop a biosimilar product and as they 
review biosimilar BLAs.”197  The FDA has also solicited feedback via public 
meetings held in Washington, D.C. focusing on multiple aspects of the BPCIA 
confronting the FDA, including scientific and technical factors.198 
These new follow-on biologic provisions raise interesting questions for 
nanomedicine products; the creation of a quicker route to market for products 
deemed biosimilar opens up questions regarding measures of “highly similar” 
and “interchangeable” that mimic those of substantial equivalence and 
bioequivalence in the context of 510(k) cleared medical devices and generic 
drugs.  Without full-scale purity, potency, and safety requirements as mandated 
by the BLA and NDA provisions, follow-on biologics will pose tough 
questions for the FDA.  One particular area will be that of combination 
products, discussed below. 
D. Combination Products 
The OCP was established in 2002,199 dividing regulatory responsibilities 
for products combining elements of drugs, devices, and biologics among the 
 
 194. Implementation of the Biologics Price Competition and Innovation Act of 2009, U.S. 
FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ 
ucm215089.htm (last visited Jan. 22, 2012). 
 195. Id. 
 196. New Acting Associate Director for Biosimilars in Office of New Drugs, U.S. FOOD & 
DRUG ADMIN., (May 17, 2010, 3:29 PM), http://www.fda.gov/AboutFDA/CentersOffices/Office 
ofMedicalProductsandTobacco/CDER/ucm217641.htm. 
 197. Id. 
 198. Approval Pathway for Biosimilar and Interchangeable Biological Products; Public 
Hearing; Request for Comments, 75 Fed. Reg. 61,497 (Oct. 5, 2010). 
 199. See Medical Device User Fee and Modernization Act of 2002, Pub. L. No. 107-250, sec. 
204, § 4(A) 116 Stat. 1588, 1611 (codified at 21 U.S.C. § 353(g)(4)(A) (2006)); see also About 
FDA: Office of Combination Products, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/About 
FDA/CentersOffices/OfficeofMedicalProductsandTobacco/OfficeofScienceandHealthCoordinatio
n/ucm2018184.htm (last visited Jan. 22, 2012).  The Safe Medical Device Act of 1990 originally 
gave primary jurisdiction to the most relevant center to regulate combination products.  Pub. L. 
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relevant Centers—CDER, CDRH, and CBER.200  Where a product contains a 
drug and a medical device, a drug and a biologic, a medical device and a 
biologic, or all three, it is termed a “combination product” and regulated 
according to the primary mode of action (“PMOA”).201  The PMOA is defined 
as “the single mode of action of a combination product that provides the most 
important therapeutic action of the combination product.”202  This 
categorization will determine the Center that will oversee the product, as well 
as the amount and type of information that the FDA will require. 
This collaborative approach to regulation has provided an important 
framework for emerging medical technologies that integrate chemical, 
mechanical, and biological aspects.  However, as acknowledged by the FDA203 
and corresponding medical agencies abroad,204 nanotechnology poses a new 
set of questions as products at the nanoscale may exhibit much more complex 
mechanisms of action(s) not easily quantified or distinguished that do not 
adhere to traditional safety, efficacy, or risk measures.205  The major regulatory 
challenge for the FDA is the fuzziness between chemical, biological, and 
mechanical aspects and modes of action with nanomedicine products and 
questions of whether existing safety measures are adequate for novel properties 
and interactions at the nanoscale. 
Particularly important for emerging nanomedicine developments, the 
FDCA distinguishes between the chemical action of drugs and the mechanical 
action of medical devices, providing that a device “does not achieve its 
primary intended purposes through chemical action within or on the body of 
man or other animals and . . . is not dependent upon being metabolized for the 
achievement of its primary intended purposes.”206  Cutting-edge nanomedicine 
applications in research and development utilize nanoscale properties in a 
 
No. 101-629, sec. 15, § 503(f)(1), 104 Stat. 4511, 4526 (1990) (codified at 21 U.S.C. § 353(f)(1) 
(Supp. II 1991)). 
 200. About FDA: Office of Combination Products, supra note 199. 
 201. 21 C.F.R. § 3.2(e), (k) (2010). 
 202. Definition of Primary Mode of Action of a Combination Product, 70 Fed. Reg. 49,848, 
49,850 (Aug. 25, 2005).  Mode of action is defined as “the means by which a product achieves its 
intended therapeutic effect or action” where “‘therapeutic’ action or effect includes any effect or 
action of the combination product intended to diagnose, cure, mitigate, treat, or prevent disease, 
or affect the structure or any function of the body.”  Id. 
 203. U.S. FOOD & DRUG ADMIN., NANOTECHNOLOGY: A REPORT OF THE U.S. FOOD AND 
DRUG ADMINISTRATION NANOTECHNOLOGY TASK FORCE 19–21 (2007), available at 
http://www.fda.gov/nanotechnology/taskforce/report2007.pdf. 
 204. EUR. MEDS. AGENCY COMM. FOR MEDICINAL PRODS. FOR HUMAN USE, REFLECTION 
PAPER ON NANOTECHNOLOGY-BASED MEDICINAL PRODUCTS FOR HUMAN USE 4 (2006). 
 205. For the earliest discussion of these problems in the legal literature, see Frederick A. 
Fielder & Glenn H. Reynolds, Legal Problems of Nanotechnology: An Overview, 3 S. CAL. 
INTERDISC. L.J. 593 (1994). 
 206. 21 U.S.C. § 321(h) (2006). 
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manner that integrate chemical, mechanical, and biological with optical, 
thermal, and other properties to respond to a given environment or outcome 
once deployed into the body.207  A single product may initially target specific 
organs and tissues in the human body, image them or take vitals, diagnose 
medical conditions, and subsequently provide medical therapies or evolve to 
address the status detected once deployed into the human body.  Rigid 
categories and time-limited assessment regarding chemical and mechanical 
aspects, as well as the identification of the primary mode of action, may hinder 
appropriate classification of evolving nanomedical products and lead to 
underregulation of novel applications. 
III.  LEGAL AND REGULATORY RESPONSES TO NANOTECHNOLOGY 
The evolution of nanotechnology over the last few decades has met with 
little attention from the FDA and other federal agencies until about 2000.  This 
is chiefly because the unifying term “nanotechnology” was not in widespread 
use until the National Science Foundation began using it to package and 
promote once disparate areas of scientific research into one unifying field 
based on the size and novel characteristics displayed at the nanoscale.208  With 
the establishment of the NNI and a resulting massive yearly infusion of 
funding for research, development, and education, nanotechnology was thrust 
onto the radar of researchers, industry, and invariably the American public. 
Despite rapid advances and the infusion of federal dollars into funding, not 
all coverage of nanotechnology has been positive nor is there unanimous 
support for the U.S. government’s aggressive funding efforts.  Many 
commentators proffer that nanotechnology research and development is too 
risky for workers exposed to nanoparticles and nanomaterials as well as 
consumers and the general population, based on a lack of information on 
toxicological, biological, environmental, and ecological effects of particles and 
materials at the nanoscale.209  Some have urged the application of the 
precautionary principle, a cry parallel to that of a previous decade in the United 
States (and adopted in the European Union) regarding genetically modified 
foods—that no nanotechnology be developed or utilized until it is shown to be 
 
 207. See, e.g., Nat’l Cancer Inst. Alliance for Nanotechnology, Nanoshells, NAT’L CANCER 
INST., http://nano.cancer.gov/learn/understanding/nanotech_nanoshells.asp (last visited Nov. 30, 
2011). 
 208. See National Nanotechnology Initiative, NAT’L SCI. FOUND., www.nsf.gov/crssprgm/ 
nano/ (last updated June 17, 2011). 
 209. For a discussion of perspectives on nanotechnology risk, see ANDREW D. MAYNARD, 
WOODROW WILSON INT’L CTR. FOR SCHOLARS, NANOTECHNOLOGY: A RESEARCH STRATEGY 
FOR ADDRESSING RISK (Project on Emerging Nanotechnologies, PEN 3, 2008) [hereinafter 
MAYNARD, ADDRESSING RISK]; see also Andrew D. Maynard, Nanotechnology: The Next Big 
Thing, or Much Ado About Nothing?, 51 ANNALS OCCUPATIONAL HYGIENE 1 (2007). 
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absolutely safe.210  Numerous reports from researchers warn that nanoparticles 
may have neurological and biological effects similar to asbestos and that the 
long-term use of nanoproducts could have far-reaching negative impact on the 
environment as they are excreted or otherwise expelled from the body or from 
consumer products.211  While compelling, these concerns are beyond the scope 
of this Article, and are addressed elsewhere. 
Academics, professional organizations, government bodies, and non-profit 
institutions alike have assessed and written on the adequacy of existing legal 
and regulatory frameworks for nanotechnology, highlighting gaps in the 
science and oversight, and identifying aspects necessitating particular 
investigation.212  While nanotechnology necessarily crosses multiple agencies 
 
 210. Robert F. Service, Nanotechnology Grows Up, 304 SCI. 1732, 1733–34 (2004). 
 211. For toxicology research on fullerenes, see, for example, J.D. Fortner et al., C60 in Water: 
Nanocrystal Formation and Microbial Response, 39 ENVTL. SCI. & TECH. 4307 (2005); Sarah B. 
Lovern & Rebecca Klaper, Dahnia Magna Mortality when Exposed to Titanium Dioxide and 
Fullerene (C60) Nanoparticles, 25 ENVTL. TOXICOLOGY & CHEMISTRY 1132 (2006); Eva 
Oberdörster, Manufactured Nanomaterials (Fullerenes, C60) Induce Oxidative Stress in the Brain 
of Juvenile Largemouth Bass, 112 ENVTL. HEALTH  PERSP. 1058 (2004).  For toxicology research 
on carbon nanotubes, see Craig A. Poland et al., Carbon Nanotubes Introduced into the 
Abdominal Cavity of Mice Show Asbestos-Like Pathogenicity in a Pilot Study, 3 NATURE 
NANOTECHNOLOGY 423 (2008); Lin Zhu et al., DNA Damage Induced by Multiwalled Carbon 
Nanotubes in Mouse Embryonic Stem Cells, 7 NANO LETTERS 3592 (2007). 
 212. See, e.g., LINDA K. BREGGIN & JOHN PENDERGRASS, WOODROW WILSON INT’L CTR. 
FOR SCHOLARS, WHERE DOES THE NANO GO? END-OF-LIFE REGULATION OF NAN-
OTECHNOLOGIES (Project on Emerging Nanotechnologies, PEN 10, 2007); J. CLARENCE DAVIES, 
WOODROW WILSON INT’L CTR. FOR SCHOLARS, NANOTECHNOLOGY OVERSIGHT: AN AGENDA 
FOR THE NEW ADMINISTRATION (Project on Emerging Nanotechnologies, PEN 13, 2008); J. 
CLARENCE DAVIES, WOODROW WILSON INT’L CTR. FOR SCHOLARS, EPA AND 
NANOTECHNOLOGY: OVERSIGHT FOR THE 21ST CENTURY (Project on Emerging 
Nanotechnologies, PEN 9, 2007); J. CLARENCE DAVIES, WOODROW WILSON INT’L CTR. FOR 
SCHOLARS, MANAGING THE EFFECTS OF NANOTECHNOLOGY (Project on Emerging 
Nanotechnologies, PEN 2, 2006); E. MARLA FELCHER, WOODROW WILSON INT’L CTR. FOR 
SCHOLARS, THE CONSUMER PRODUCT SAFETY COMMISSION AND NANOTECHNOLOGY (Project 
on Emerging Nanotechnologies, PEN 14, 2008); MARK GREENWOOD, WOODROW WILSON INT’L 
CTR. FOR SCHOLARS, THINKING BIG ABOUT THINGS SMALL: CREATING AN EFFECTIVE 
OVERSIGHT SYSTEM FOR NANOTECHNOLOGY (Project on Emerging Nanotechnologies, PEN 7, 
2007); SAMUEL N. LUOMA, WOODROW WILSON INT’L CTR. FOR SCHOLARS, SILVER 
NANOTECHNOLOGIES AND THE ENVIRONMENT: OLD PROBLEMS OR NEW CHALLENGES? (Project 
on Emerging Nanotechnologies, PEN 15, 2008); MAYNARD, ADDRESSING RISK, supra note 209; 
NANOACTION, INTERNATIONAL CENTER FOR TECHNOLOGY ASSESSMENT, PRINCIPLES FOR THE 
OVERSIGHT OF NANOTECHNOLOGIES AND NANOMATERIALS (2007) available at http://www.icta. 
org/doc/Principles%20for%20the%20Oversight%20of%20Nanotechnologies%20and%20Nanom
aterials_final.pdf; NAT’L NANOTECHNOLOGY INITIATIVE, NAT’L SCI. & TECH. COUNCIL, 
ENVIRONMENTAL, HEALTH, AND SAFETY RESEARCH NEEDS FOR ENGINEERED NANOSCALE 
MATERIALS (2006) available at http://www.nano.gov/NNI_EHS_research_needs.pdf; NAT’L 
RES. COUNCIL, REVIEW OF THE FEDERAL STRATEGY FOR NANOTECHNOLOGY-RELATED 
ENVIRONMENTAL, HEALTH, AND SAFETY RESEARCH (2008); WILLIAM B. SCHULTZ & LINDA 
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that regulate public and worker safety, the environment, national security, and 
consumer products, the FDA will oversee the majority of nanomedicine 
products on the market. 
Although extremely incremental, the FDA has initiated some agency 
information-gathering actions to begin to contemplate novel issues raised by 
nanotechnology products and applications.  The FDA has installed a 
Nanotechnology Task Force,213 fostered intra-agency Center collaborations, 
begun to implement internal agency policies relating to nanotechnology, and 
published draft guidance for industry.214  Specifically, in May 2010, the FDA’s 
CDER and the Research Office of Pharmaceutical Science issued a policy 
instructing drug reviewers to collect nanospecific information from new drug 
applications.215  To date, the CDER is the only Center to adopt internal policy 
regarding nanotechnology. 
Although this section will primarily focus on FDA responses to 
nanotechnology, an initial examination of international, state, and local 
government actions are instructive to highlight how the piecemeal and 
uncoordinated efforts at information-gathering and oversight have thus far 
progressed. 
A. State, Local, and International 
In light of the lack of nano-specific oversight mechanisms at the federal 
level, the City of Berkeley and the State of California have taken small steps in 
gathering information on nanotechnology in order to track its use by mandating 
the reporting of nanoparticle and nanomaterial manufacturing.  Berkeley, 
 
BARCLAY, WOODROW WILSON INT’L CTR. FOR SCHOLARS, A HARD PILL TO SWALLOW: 
BARRIERS TO EFFECTIVE FDA REGULATION OF NANOTECHNOLOGY-BASED DIETARY 
SUPPLEMENTS (Project on Emerging Nanotechnologies, PEN 17, 2009); MICHAEL R. TAYLOR, 
WOODROW WILSON INT’L CTR. FOR SCHOLARS, ASSURING THE SAFETY OF NANOMATERIALS IN 
FOOD PACKAGING: THE REGULATORY PROCESS AND KEY ISSUES (Project on Emerging 
Nanotechnologies, PEN 12, 2008); MICHAEL R. TAYLOR, WOODROW WILSON INT’L CTR. FOR 
SCHOLARS, REGULATING THE PRODUCTS OF NANOTECHNOLOGY: DOES FDA HAVE THE TOOLS 
IT NEEDS? (Project on Emerging Nanotechnologies, PEN 5, 2006) [hereinafter TAYLOR, 
REGULATING THE PRODUCTS OF NANOTECHNOLOGY]; U.S. ENVTL. PROT. AGENCY, 
NANOTECHNOLOGY WHITE PAPER (2007), available at http://es.epa.gov/ncer/nano/publications/ 
whitepaper12022005.pdf; Kenneth W. Abbott et al., A Framework Convention for 
Nanotechnology?, 36 Envtl. L. Rep. (Envtl. Law Inst.) 10,931 (2006); Jordan Paradise et al., 
Developing Oversight Frameworks for Nanobiotechnology, 9 MINN. J. L. SCI. & TECH. 399 
(2008); Mihail C. Roco, Possibilities for Global Governance of Converging Technologies, 10 J. 
NANOPARTICLE RES. 11 (2008); ABA Section of Env’t, Energy, & Res., Nanotechnology 
Project, ABA, http://www.americanbar.org/groups/environment_energy_resources/projects_ 
awards/nanotech.html (last visited Nov. 30, 2011). 
 213. U.S. FOOD & DRUG ADMIN, supra note 203, at 5. 
 214. See infra Part III.C.2–4. 
 215. MAPP 5015.9 REPORTING FORMAT, supra note 21, at 3–4. 
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California requires that manufacturers report yearly to the Toxics Management 
Division on certain aspects of their manufacturing processes and products.216  
The California Department of Toxic Substances and Control issued letters in 
January 2009 to select manufacturers identified as producing nanoparticles or 
nanomaterials, requesting nano-specific data on carbon nanotubes and methods 
of worker protection.217  The California legislature had authorized the 
Department to request information on chemicals of concern.218  In a joint effort 
with the California Council on Science and Technology, the California 
Department of Toxic Substances issued a report in January 2010 detailing 
enabling legislative provisions, areas of inquiry, and the general status of 
nanotechnology research and manufacturing in California.219  To date, no other 
state or municipality has followed California’s lead. 
Internationally, other countries are also at early stages of understanding the 
scope of the unique legal and scientific questions that nanotechnology may 
raise.  While no countries have enacted nano-specific legislation, there have 
been some efforts to initiate reporting and tracking mechanisms.  A voluntary 
reporting scheme was implemented in the United Kingdom, but published 
reports indicate that authorities received an abysmally low number of 
submissions in response.220  In 2004, the Royal Society and Royal Academy of 
Engineering were commissioned by the British government to examine 
oversight of manufactured nanoparticles and recommended that a ban on free 
(rather than fixed in a matrix) manufactured nanoparticles in environmental 
applications be implemented;221 there has been no movement to implement that 
ban.222  It appeared from media reports in 2009 that Canada was to claim the 
 
 216. BERKELEY, CAL., MUNICIPAL CODE §§ 15.12.040(I), 15.12.050(C)(7) (2008). 
 217. Carbon Nanotube Information Call-in, CAL. DEP’T OF TOXIC SUBSTANCES CONTROL, 
http://www.dtsc.ca.gov/TechnologyDevelopment/Nanotechnology/CNTcallin.cfm (last visited 
Nov. 30, 2011).  The Department’s future schedule of inquiry to manufacturers in the state over 
the next few years includes nano silver, reactive nonmetals, dendrimers, and quantum dots. 
 218. CAL. HEALTH & SAFETY CODE §§ 57019–57020 (West Supp. 2011). 
 219. CAL. COUNCIL ON SCI. AND TECH., NANOTECHNOLOGY IN CALIFORNIA (2010), 
available at http://www.ccst.us/publications/2010/2010Nano.pdf. 
 220. DEP’T FOR ENV’T, FOOD & RURAL AFFAIRS, UK VOLUNTARY REPORTING SCHEME FOR 
ENGINEERED NANOSCALE MATERIALS  4 (2008) (U.K.), available at http://www.defra.gov.uk/en 
vironment/nanotech/policy/pdf/vrs-nanoscale.pdf; Archive: Nanotechnology: Policy, DEP’T FOR 
ENV’T, FOOD AND RURAL AFFAIRS, http://archive.defra.gov.uk/environment/quality/nanotech/ 
policy.htm (last visited Nov. 30, 2011) (stating that DEFRA received only thirteen submissions 
during the two years of the study). 
 221. THE ROYAL SOC’Y & THE ROYAL ACAD. OF ENG’G, NANOSCIENCE AND 
NANOTECHNOLOGIES: OPPORTUNITIES AND UNCERTAINTIES 85 (2004), available at 
http://www.nanotec.org.uk/report/Nano%20report%202004%20fin.pdf. 
 222. Although the U.K. government issued a response, no further information is available.  
See The Royal Soc’y & The Royal Acad. of Eng’g, Nanotechnology and Nanoscience, 
NANOTEC.ORG, http://www.nanotec.org.uk/govRes.htm (last visited Nov. 30, 2011). 
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role of being the first country to enact law regarding reporting and monitoring 
of nanomaterials,223 although the bill has yet to become law.  Bill C-494, 
introduced in March 2010, would have amended the Canadian Environmental 
Protection Act.224 
Australia commissioned Monash University academics to examine that 
country’s existing legal frameworks; they concluded that there were significant 
gaps when those frameworks were applied to nanotechnology.225  The 
European Economic and Social Committee of the European Parliament 
recommended in a 2005 opinion that the European Commission develop 
methods to identify nanotechnology risks, setting a recommended timeframe of 
2008.226  Similar to many other countries and regions examining these issues in 
terms of law and regulations, the European Parliament has not yet responded. 
B. Federal Administrative Agencies 
As nanotechnology is truly a convergence of scientific fields and 
disciplines, spanning a vast spectrum of research and product development 
both in the United States and internationally, U.S. federal agencies have 
struggled to keep abreast of the rapidly increasing scientific and technological 
capabilities, applications, and marketed consumer products at the nanoscale.  
In the face of myriad unknowns regarding health and environmental effects of 
nanoparticles and nanomaterials, federal agencies have proceeded to measure, 
evaluate, approve, and monitor nanotechnology processes and products under 
existing legal and regulatory frameworks.  Although a number of U.S. federal 
regulatory agencies have taken the initiative to either implement voluntary 
nanotechnology-specific reporting mechanisms,227 begin expert investigations 
 
 223. Victoria Gill, Nanotechnology Regulation Creeps Closer, CHEMISTRY WORLD (Feb. 25, 
2009), http://www.rsc.org/chemistryworld/News/2009/February/25020901.asp. 
 224. See An Act to Amend the Canadian Environmental Protection Act, 1999, 
(nanotechnology), Bill C-494 (Historical), 40th Parl., 3d. Session (Can. 2010), available at 
http://parl.gc.ca/content/hoc/Bills/403/Private/C-494/C-494_1/C-494_1.pdf. 
 225. KARINNE LUDLOW ET AL., A REVIEW OF POSSIBLE IMPACTS OF NANOTECHNOLOGY ON 
AUSTRALIA’S REGULATORY FRAMEWORK 8, 100 (2007), available at http://www.innovation. 
gov.au/Industry/Nanotechnology/NationalEnablingTechnologiesStrategy/Documents/MonashRep
ort2007.pdf. 
 226. Opinion of the European Economic and Social Committee on the ‘Communication from 
the Commission to the Council, the European Parliament and the Economic and Social 
Committee—Nanosciences and Nanotechnologies: An action Plan for Europe 2005-2009,’ 2006 
O.J. (C 185) 1, available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2006: 
185:0001:0009:en:pdf. 
 227. Although subsequently acknowledging that it has largely failed, EPA instituted a 
voluntary program for industry to provide information relevant to health and safety for industrial 
applications of nanotechnology and nanomaterials.  OFFICE OF POLLUTION PREVENTION & 
TOXICS, U.S. ENVT’L PROT. AGENCY, NANOSCALE MATERIALS STEWARDSHIP PROGRAM: 
INTERIM REPORT 3, 6 (2009), available at http://epa.gov/oppt/nano/nmsp-interim-report-final.pdf. 
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into specific questions regarding nanotechnology safety or risks,228 clarify 
existing regulations and policies in light of nanotechnology,229 or create 
internal methods of categorizing nanotechnology developments or products 
within their purview,230 for the most part agencies are operating on a business 
as usual mode for nanotechnology. 
Specifically, the EPA has published two notices in the Federal Register 
applicable to nanotechnology products. The first instructs that the EPA will 
regulate engineered carbon nanotubes under the Toxic Substances Control 
Act.231  The second clarifies that the Federal Insecticide Fungicide and 
Rodenticide Act applies to product claims involving ion-generating silver 
pesticides.232  This clarification notice for silver pesticides, while not specific 
to nanotechnology, was a response to petitions regarding Samsung’s marketing 
claims that its silver ion-generating washing machine utilized nanotechnology 
in the form of germ-killing silver nanoparticles.233 
The U.S. Patent and Trademark Office (“USPTO”) has also taken steps to 
deal with the expanse of nanotechnology patent applications by creating a 
nanotechnology patent class.  One source reports that the USPTO began 
issuing nanotechnology-related patents as early as 1976.234  In developing a 
nanotechnology classification system, the USPTO created a framework that 
attempts to advance uniformity in classifying nanopatents in an effort to 
standardize the terminology, create an effective system for disclosure and 
cross-referencing, assist inventors and examiners in identifying and reviewing 
 
 228. U.S. FOOD & DRUG ADMIN., supra note 203, at 20. 
 229. Toxic Substances Control Act Inventory Status of Carbon Nanotubes, 73 Fed. Reg. 
64,946 (Oct. 31, 2008); Pesticide Registration; Clarification for Ion-Generating Equipment, 72 
Fed. Reg. 54,039 (Sept. 21, 2007). 
 230. See, e.g., MAPP 5015.9 REPORTING FORMAT, supra note 21, at 4–5; U.S. PATENT & 
TRADEMARK OFFICE, CLASSIFICATION DEFINITIONS: CLASS 977 NANOTECHNOLOGY (2010), 
available at http://www.uspto.gov/web/patents/classification/uspc977/defs977.pdf [hereinafter 
CLASS 977 DEFINITIONS]. 
 231. Toxic Substances Control Act Inventory Status of Carbon Nanotubes, 73 Fed. Reg. at 
64,946. 
 232. Pesticide Registration; Clarification for Ion-generating Equipment, 72 Fed. Reg. at 
54,039. 
 233. Susan Morrissey, Reclassifying Nanosilver: EPA Will Now Consider Nanosilver Used in 
Washing Machines as Pesticides, CHEMICAL & ENG’G NEWS, Dec. 4, 2006, at 14, 14, available 
at http://pubs.acs.org/cen/news/84/i49/8449notw7.html (last visited Nov. 30, 2011). 
 234. Tyson Winarski & Elizabeth Stoker-Townsend, Nanotechnology Thriving on Patents, 
INTELL. PROP. TODAY, Apr. 2005, at 26, 26 (attributing information to the National Science 
Foundation).  However, the first patent within the USPTO patent classification system was filed 
in September 1975 and issued in August 1978.  Injectable Compositions, Nanoparticles Useful 
Therein, and Process of Mfg. Same, U.S. Patent No. 4,107,288 (filed Sept. 9, 1975). 
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relevant prior art, and decrease inadvertent patent infringement.235  As a result 
of the USPTO’s efforts, there are currently over 7410 patents classified as 
nanotechnology-related inventions236 under five broadly delineated areas,237 
divided into 263 subclasses.238  While suffering from numerous 
shortcomings,239 these actions by the USPTO serve as an example for other 
 
 235. Jordan Paradise, Claiming Nanotechnology: Improving USPTO Efforts at Classification 
of Emerging Nano-Enabled Pharmaceutical Technologies, 10 NW. J. TECH. & INTELL. PROP. 
169, 184 (2012). 
 236. This number is based on the author’s search of the USPTO website at http://patft.uspto. 
gov/netahtml/PTO/search-adv.htm using the “Advanced Search” function and the 977 
classification as the single search term (enter ccl/977/$ into the query box).  An identical search 
of the published patent applications at http://appft1.uspto.gov/netahtml/PTO/search-adv.html 
identified 10,613 applications that fall into the 977 classification.  Searches performed Nov. 30, 
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 237. CLASS 977 DEFINITIONS, supra note 230.  The five broad areas under the 977 class are: 
(1) nanostructures and chemical compositions; (2) devices that include at least one nanostructure; 
(3) mathematical algorithms; (4) methods or apparatuses for making, detecting, analyzing or 
treating nanostructure; (5) and specified uses of nanostructures.  Id. 
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977-10 to -40. 
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the properties and functioning at the nanoscale that were unknown in decades past.  For example, 
early patent claims may conflate the macro, micro, and nanoscale in a manner that is problematic 
for later inventions that identify and harness something present at a range in the nanoscale and not 
at the micro or macro scale.  Another concern is the convergence of technologies at the nanoscale, 
in that overlapping patents and claims may cross multiple technologies, with many issued before 
“nano” was a widespread word.  Many of these concerns will abate given the USPTO’s 
classification system as patenting moves forward, although questions will arise with regard to 
inventions submitted and patents issued prior to the development of the classification system.  In 
performing the cross-listing classifications, the USPTO is merely putting issued patents into those 
263 subclasses and not making determinations on claim scope and potential infringement from 
one patent to the next, except as part of the evaluation of prior art.  For academic perspectives, 
see, for example, Indrani Barpujari, The Patent Regime and Nanotechnology: Issues and 
Challenges, 15 J. INTELL. PROP. RTS. 206 (2010); Diana M. Bowman & Graeme A. Hodge, A 
Small Matter of Regulation: An International Review of Nanotechnology Regulation, 8 COLUM. 
SCI. & TECH. L. REV. 1 (2007); K. Eric Drexler & Jason Wejnert, Nanotechnology and Policy, 45 
JURIMETRICS J. 1 (2004); Fiedler & Reynolds, supra note 205; Ernest J. Getto et al., 
Nanotechnology: Will Tiny Particles Create Large Legal Issues?, SCITECH LAW., Summer 2009, 
at 6; Mark A. Lemley, Patenting Nanotechnology, 58 STAN. L. REV. 601 (2005); Thomas M. 
Mackey, Nanobiotechnology, Synthetic Biology, and RNAI: Patent Portfolios for Maximal Near-
Term Commercialization and Commons for Maximal Long-Term Medical Gain, 13 MARQ. 
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federal agencies in terms of gathering information relevant to nanotechnology 
and categorizing nano-specific features that could be useful in the future as 
more becomes known about products, uses, and potential risks of 
nanotechnology.  Utilization and effective linking of this information among 
agencies could serve as a mechanism to fill in the information gaps currently 
confronting other relevant agencies. 
Aside from these actions by the EPA, the USPTO, and, as described 
below, the FDA, thus far federal executive agencies responsible for the 
oversight of the spectrum of nanotechnology products have utilized existing 
laws, regulations, policy, and institutional structures to govern these products.  
The authority of these agencies and the administrative tools available to them 
are diverse and vary greatly across domains.  Basic administrative law 
concepts instruct that federal agencies operate within the authority vested in 
them by Congress under the enabling statute and subsequent statutes, and 
construed by the courts.  Agencies are able to promulgate regulations or 
adjudicate individual instances within the bounds of this authority and mandate 
from Congress.  Agency policy and procedures, public and internal guidance, 
advisory opinions, and a variety of other agency documents serve to clarify and 
interpret statutes and regulations; while not having the force of law, these 
documents all contribute to “oversight” in a broad sense. 
This section has focused on a discussion of the creation and application of 
agency-promulgated regulations, the development of public and internal 
guidance, as well as methods of information gathering that agencies have 
initiated in the nanotechnology realm such as reporting mechanisms and 
internal classification schemes.  Part III.C and Part IV will address the capacity 
of the current statutory and regulatory scheme to deal with nanotechnology.  
This Article urges that the FDA’s broad mandate from Congress and scope of 
authority with regard to drugs, medical devices, and biologics provide ample 
opportunity for the Agency to develop requirements for enhanced data and 
information from industry to inform its assessment of the characteristics and 
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properties of nanotechnology products, as well as the assessment of both short 
and long-term public health effects. 
C. The Food and Drug Administration 
The FDA utilizes existing statutory provisions240 and regulatory pathways 
to review nanomedicine products falling within its oversight.241  This has 
provoked debate from those that believe that nanotechnology warrants its own 
oversight provisions.242  The FDA and other agencies struggle with a dearth of 
observed or reported health or safety issues traceable to any nano-
characteristics of a product; this serves as the basis of the FDA’s position that 
the current system thus far provides adequate assurances for safety and 
efficacy in the case of new drugs and high risk medical devices, 
bioequivalence in the case of generic drugs, and substantial equivalence in the 
case of lower risk medical devices.243 
Nanotechnology-based research and development activity in medical and 
health applications is booming.  While many nanotechnology-based medical 
device products are entering the market (such as in vitro diagnostics and 
imaging tools, dental products, bone repair systems, and tissue reinforcement 
products), nanomedicine is currently dominated by drugs and drug-delivery 
applications, accounting for about three-quarters of the emerging 
nanomedicine market.244  These rapidly developing applications in 
nanomedicine often integrate mechanical, chemical, electrical, and optical 
properties at the nanoscale.245  As discussed previously, unlike products at the 
macroscale and microscale, the distinction between chemical and mechanical 
action are not easily distinguishable or measurable at the nanoscale.246 While 
this distinction between chemical, electrical, mechanical, and optical properties 
is not critical for the science to evolve, it is extremely important in determining 
which regulatory pathway a company will need to pursue for any given 
product, as the dividing line between a drug and a device has traditionally been 
drawn in terms of whether it acts chemically (is metabolized by the body) or 
 
 240. Federal Food, Drug & Cosmetic Act, 21 U.S.C. §§ 301–99 (2006). 
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mechanically.247  This ties directly to categorization as a drug, device, or 
biologic, and whether abbreviated routes to market are available. 
The FDA has taken the following steps with regard to nanotechnology: 
forming a multi-center task force, instituting a CDER-specific internal policy, 
publishing draft guidance for industry, soliciting public comments through 
public meetings, and partnerships with research institutions to examine 
particular aspects of nanotechnology. 
1. Nanotechnology Task Force 
An FDA Task Force was convened in response to several citizen petitions 
aimed at perceived gaps in oversight for consumer products containing 
nanoparticles.248  To investigate generally whether existing provisions continue 
to encourage development of safe, effective and innovative products using 
nanotechnology and also address specific issues raised in the petitions, the 
FDA established the Nanotechnology Task Force comprised of authorities in 
the CBER, CDER, and CDRH.249  In July 2007, the FDA’s Nanotechnology 
Task Force issued a report indicating that no new regulatory categories were 
needed for drug, medical device, and food products that contained 
nanoparticles or nanomaterials or were manufactured using nanotechnology.250  
However, the report also urged that the Agency must continuously monitor and 
understand the science in order to appropriately apply regulations in the future 
and suggested that Centers should consider issuing guidance for industry.251  
The report flagged combination products utilizing nanoscale materials as 
potentially problematic, acknowledging novel issues for regulation due to their 
dynamic quality based on size and “their potential for diverse applications.”252  
Specifically, it provided: 
The very nature of nanoscale materials—their dynamic quality as the size of 
nanoscale features change, for example, and their potential for diverse 
applications—may permit the development of highly integrated combinations 
of drugs, biological products, and/or devices, having multiple types of uses, 
such as combined diagnostic and therapeutic intended uses.  As a consequence, 
the adequacy of the current paradigm for selecting regulatory pathways for 
“combination products” may need to be assessed to ensure predictable 
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determinations of the most appropriate pathway for such highly integrated 
combination products.253 
2. CDER Manual of Policies and Procedures 
Specific to drugs, the FDA’s CDER and the Research Office of 
Pharmaceutical Science issued an internal Manual of Policies and Procedures 
(“MaPP”) in May 2010 that instructs drug reviewers to capture “relevant 
information about nanomaterial-containing drugs” that will be entered into a 
nanotechnology database.254  The MaPP states that “in order to develop 
guidance for industry, CDER needs to organize all the data submitted in 
support of nanotechnology-based drug applications,”255 gather all “relevant 
information about nanomaterial-containing drugs” and enter them into a 
nanotechnology database maintained by the Agency.256  Of interest for the 
synthesis of data at the nanoscale, the MaPP defines the terms 
nanomaterial/nanoscale material (“[a]ny materials with at least one dimension 
smaller than 1,000nm”); nanomedicine (“[t]he use of nanoscale materials for 
medical applications”); and characterization (“[p]hysicochemical evaluation of 
relevant drug properties”).257 
An important feature of the MaPP definitions is the range included in the 
CDER’s conception of nanoscale as 1–1,000nm compared to the NNI 
definition extending from 1–100nm.258  This range suggests that the FDA has 
determined, as many scientists have argued for years,259 that nanotechnology 
cannot be fit precisely into a range under 100nm, as the size-dependent novel 
properties vary with the material, environment, and interactions.  While this 
MaPP serves an internal information-gathering purpose and imposes no 
additional requirements on drug applicants, it signals recognition of the nascent 
state of understanding of the complex science of nanotechnology in human 
drugs. 
The MaPP provides several attachments that drug reviewers are instructed 
to complete for each drug application falling into the nanoscale classification.  
The first is a list of nanotechnology product evaluation questions.260  These 
questions include identification of the type of nanoscale materials in the 
product, whether it is a reformulation of a previously-approved product, 
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whether it is soluble or insoluble in an aqueous environment, the range of the 
nanomaterial, the reported particle size, other reported properties, and methods 
used to characterize the nanomaterial.261  Another attachment details the 
template for the format of the drug product database entry, including basic 
descriptions of the product (e.g., drug name, indication, route of 
administration, sponsor, approval date, Center division), particle size range, 
and technique for assessing the nanospecific properties.262  The database entry 
also includes website links to quality reviews, clinical reviews, ClinPharm 
reviews, and PharmTox reviews.263  These last four database entries could be 
especially useful for ongoing evaluation of the toxicological effects and cross-
linking of similar products either by FDA or outside experts or advisory 
committees if made publically available or available to a segment of 
specialists.  A third attachment provides a product review flow chart, 
visualizing the series of questions posited in the first attachment 
questionnaire.264 
While this internal procedure is in early stages, it has the potential to 
generate an abundance of nano-specific information in the context of drug 
products approved by the CDER.  Other FDA Centers should implement 
similar procedures for products within their regulatory authority, using the 
CDER MaPP as a guide for structuring this information.  This will be 
particularly illuminating for post-market tracking of combination 
nanotechnology products that are classified for oversight purposes by their 
PMOA; it may be that as information accumulates regarding patient use and 
potentially adverse events that the FDA may want to reassess the use of PMOA 
measures for nanotechnology-based nanomedicine products.  For example, 
where a nano combination product is classified as a medical device based on 
its mechanical properties rather than a drug based on its chemical properties 
(which would mandate more extensive clinical trials to satisfy safety and 
efficacy measures), it may later become apparent through post-market studies 
or event reporting that the unique characteristics that make the product “nano” 
behave in a manner that necessitates a drug-like approval process instead to 
most adequately assure safety and efficacy. 
3. Draft Guidance for Industry 
On June 9, 2011, the FDA released draft guidance for industry laying out 
the Agency’s “current thinking on whether FDA-regulated products contain 
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nanomaterials or otherwise involve the application of nanotechnology.”265  The 
guidance urges that the document does not establish legally enforceable 
obligations, but should be viewed only as recommendations for the industry.266  
It “does not establish any regulatory definitions” or “address the regulatory 
status of products,” but does state that future additional guidance may be 
issued for specific product or classes of products.267  Published concurrently 
with an announcement on policy principles for nanotechnology regulation from 
the Office of Science and Technology Policy (“OSTP”),268 the draft guidance 
exemplifies the ongoing battle by federal administrative agencies to quantify, 
categorize, and regulate nanotechnology.  The deadline for written comments 
was August 15, 2011. 
Framed as two general points to consider applicable to both new products 
and any manufacturing changes to FDA-approved and cleared products, the 
draft guidance provides both a dimensional aspect—“[w]hether an engineered 
material or end product has at least one dimension in the nanoscale range 
(approximately 1nm to 100 nm)”—and a behavioral aspect—“[w]hether an 
engineered material or end product exhibits properties or phenomena, 
including physical or chemical properties or biological effects, that are 
attributable to its dimension(s), even if these dimensions fall outside the 
nanoscale range, up to one micrometer.”269  Notably, the second point expands 
the first dimensional aspect beyond the 100 nm range if the properties 
exhibited are tied directly to its dimensions up to one micrometer (also called a 
micron).270 
Supporting its two points, the guidance also provides the Agency’s 
rationale for the elements contained within the points to consider.  These 
largely recite the current state of knowledge of nanoscale properties and 
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phenomena as the underpinnings of the two points.271  Specifically, the FDA 
distinguishes the “deliberate manipulation and control of particle size” of an 
engineered material or end product from the natural functioning at the 
nanoscale, identifies the traditional bounds of the nanoscale encompassing 
1nm to 100nm as serving merely as “a first [dimensional] reference point” for 
industry, highlights the relationship between size and physical and chemical 
properties as important for questions of safety and efficacy, and explains the 
broadening of dimensions of “nanoscale” up to one micrometer as linking to 
the use of agglomerates and aggregates that may coat or functionalize a 
product.272 
4. Public Input 
The FDA has also utilized requests for public comments in order to gather 
information on the scientific aspects of nanotechnology.  The FDA has held 
several public meetings: October 2006 to aid in developing the 
Nanotechnology Task Force Report;273 September 2008 to gather information 
to assist the Agency in implementing recommendations laid out in the 
Nanotechnology Task Force Report;274 and September 2010 to solicit data and 
information on biocompatibility assessment of diagnostics and devices that 
include nanomaterials.275  The FDA also maintains materials for the public on 
its web page regarding nanotechnology.276 
5. Research Efforts 
The FDA as an agency does not see much investment for basic research;277 
however, the FDA is encouraging nanotechnology research in a number of 
areas in order to inform agency decisions.  The FDA is collaborating with the 
NIH as part of the National Toxicology Program to address specific product 
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concerns.278  The National Cancer Institute’s Nanotechnology Characterization 
Laboratory, together with the FDA and the National Institute of Standards and 
Technology, is conducting “preclinical efficacy and toxicity testing of 
nanoparticles” in an effort to identify appropriate standards for molecular-sized 
cancer drugs.279  The FDA has identified its areas of interest, such as risk 
characterization based on physical and chemical properties, in vitro and in vivo 
models to assist in predictions of human response to exposure, quantification 
methods, measures of adsorption and transport in the human body, and 
relationships between nanomaterial properties and the human body in terms of 
uptake via the skin, lungs, and gastrointestinal tract.280 
The FDA also boasts several public-private partnerships, including a 
partnership with Johns Hopkins University and the Houston-based Alliance for 
NanoHealth (“ANH”).  The objectives of the collaboration with Johns Hopkins 
are laid out as development of relationships for training and outreach and 
development of collaboration among government and academia.281  The ANH 
collaboration aims to “help speed development of safe and effective medical 
products in the emerging field of nanotechnology,” which entails the FDA and 
the ANH “work[ing] to expand knowledge of how nanoparticles behave and 
affect biologic systems, and to facilitate the development of tests and processes 
that might mitigate the risk associated with nanoengineered products.”282 
While only an initial foray into oversight of nanotechnology by the FDA, 
these moves reflect an incremental and coordinated effort among various FDA 
Centers, including the CDER, CBER, CDRH, and the Center for Food Safety 
and Nutrition (“CFSAN”) on issues with nanotechnology products. 
IV.  MOVING FORWARD—ASSESSING OVERSIGHT OPTIONS FOR EMERGING 
NANOTECHNOLOGY COMBINATION PRODUCTS 
The previous two sections illustrate the growing importance of 
nanotechnology in the spectrum of drug, device, and biological applications 
reviewed by the FDA.  They also highlight the current uncertainty surrounding 
how to appropriately regulate these products.  As previously discussed, the 
FDA first categorizes such products as a drug, device, or biologic and only 
then applies safety and efficacy requirements.283  This categorization 
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determines whether the product will be subject to the most rigorous safety and 
efficacy measures (NDAs for new drugs, PMAs for highest risk medical 
devices, and BLAs for biologics) or whether it will be subject only to measures 
of bioequivalence, substantial equivalence, or biosimilarity.  As previously 
noted, it appears most nanodrugs are entering the market through the 
premarket approval process requiring safety and efficacy (although some have 
proceeded to market on an accelerated basis based on promise for treatment of 
life-saving or serious diseases), while most nanomedical devices have been 
cleared through the less rigorous 510(k) process requiring only a showing of 
substantial equivalence to a predicate device.284  Biologics have been subject to 
safety and efficacy testing as set out in the PHSA; as described in Parts II.C 
and D, it remains to be seen how the biosimilars pathway will unfold.  The 
regulatory pathways are becoming troublingly Byzantine.  As is described 
above, the discontinuities and silo effects in the current system pose real 
concerns for long-term safety. 
This section urges that the FDA utilize increased data gathering, 
monitoring and tracking of nano-specific features and outcomes, as well as 
strengthened collaborative approaches within the Agency, to bolster its 
treatment of nanotechnology.  While not urging application of the 
precautionary principle, this Article does argue that the FDA can, and should, 
be doing more to address the uncertainties and safety concerns.  This section 
classifies suggestions for change into several areas: first, implementing general 
coordination among agencies at the federal level; second, the possibility of 
organizational restructuring within the FDA; and third, necessary regulatory 
and policy changes within the FDA to address issues of safety and monitoring 
of approved nanoproducts. 
A. The Need for a Strong Nanotechnology Coordinating Entity 
In order for any collaborative model to succeed, a strong coordinating 
entity must be created to facilitate efforts at assessing and adapting oversight 
of nanotechnology among federal, state, and local agencies.  The presence of a 
well-funded national coordinating entity for contemplation of nanotechnology 
oversight would assist in synthesizing and applying the emerging findings 
regarding nanotechnology characterization, measurements, and risk assessment 
and would lead a more unified, and unifying, approach to development of 
mechanisms of oversight for emerging nanotechnologies.  This is not to 
suggest, as some esteemed scholars have, that in order to effectively deal with 
nanotechnology Congress needs to set up a singular federal agency to regulate 
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all nanotechnology products.285  This vision merely urges more collaboration 
among agencies wrestling with oversight generally, and regulation and policy 
specifically, in the area of nanotechnology. 
The most promising entity within the federal government to serve this role 
is the NNI.  Created in 2000, and situated within the framework of the National 
Science and Technology Council as a national coordinating entity for 
nanotechnology research, development and education, the NNI has been the 
federal vehicle for extensive mobilization and allotment of nanotechnology 
funding.286  The NNI, which serves as coordinating entity for agencies dealing 
with nanotechnology, does not have a specific mission or aim involving legal 
and policy coordination.  Although it fosters collaborative efforts in research 
and education among the agencies, none of the almost ten billion dollars spent 
on the NNI from 2001–2009287 has been devoted to tackling perhaps the most 
challenging problem facing these regulatory agencies: how to regulate and 
oversee the products resulting from this massive national investment. 
The NNI does currently have a Nanotech Environmental and Health 
Implications Working Group that “provides a forum for focused interagency 
collaborations on EHS [environmental, health, and safety implications] and 
leadership in establishing . . . the EHS research agenda, in addition to 
communicating EHS information between NNI agencies and to the public.”288  
Likewise, the National Nanotechnology Initiative Amendments of 2009289 
provide multiple subgroups under the OSTP for research coordination 
regarding environment, health and safety, and public engagement.290  Either a 
separate oversight-specific subgroup could be created or these existing 
subgroups could be more effectively utilized to address oversight and policy 
questions. 
Unfortunately, Congress and the NNI missed the opportunity to institute 
such an oversight-contemplating arm as part of the ten-year renewal of the 
initiative.  The NNI recently asked for public comment on its Strategic Plan for 
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the 2011 fiscal year, including targeted aims of “foster[ing] the transfer of new 
technologies into products for commercial and public benefit” and 
“responsibly translating . . . knowledge [of the fundamental scientific science] 
into practical applications.”291  In February, the NNI published its 2011 
Strategic Plan, highlighting four goals: advancing a world-class 
nanotechnology research and development program; fostering the transfer of 
new technologies into products for commercial and public benefit; developing 
and sustaining educational resources, a skilled workforce, and the supporting 
infrastructure and tools to advance nanotechnology; and supporting the 
responsible development of nanotechnology.292  While the NNI’s fourth goal 
alludes generally to public health and the ethical, legal, and social implications 
of nanotechnology development, it does not include the development of 
collaborative structures to wrestle with questions of oversight raised by 
nanotechnology and the importance of partnering evolving scientific 
information into regulatory decisions and frameworks of the federal 
agencies.293 
However, as is typically the case with emerging technologies where federal 
agencies are faced with scientific uncertainty and a lack of assessment 
measures, large-scale coordination is often cumbersome due to differences in 
statutory authority, regulatory missions, resources, priorities, and various other 
factors.  Feasibility is a limiting factor for such coordination. 
B. Restructuring the FDA 
Congress and the FDA have endured long-standing complaints that the 
categorical statutory and regulatory approach has caused a silo effect among 
product areas depending largely on definition through amendments to the 
FDCA spurred by reactions to large-scale events threatening public health and 
safety.294  While Congress could contemplate the creation of a nanotechnology 
specific Center or Office within the FDA, this would exacerbate the silo effect 
by further segregating products based on definitional and categorical aspects.  
A more workable model would be adjustments within the FDA by the 
Commissioner to foster increased collaboration among the CDER, CBER, and 
CDRH perhaps drawing on the established multi-center Nanotechnology Task 
 
 291. NNI Strategic Plan 2010; Request for Information, 75 Fed. Reg. 38,850, 38,850 (July 6, 
2010). 
 292. SUBCOMM. ON NANOSCALE SCI., ENG’G, & TECH., supra note 60, at 23–32. 
 293. Id. at 30–32.  One scholar has specifically urged President Obama to strengthen the 
oversight role of the NNI and separate it from the promotional role of the NNI in his assessment 
of the current status of oversight relevant to nanotechnology.  See J. CLARENCE DAVIES, 
WOODROW WILSON INT’L CTR. FOR SCHOLARS, NANOTECHNOLOGY OVERSIGHT: AN AGENDA 
FOR THE NEW ADMINISTRATION 8–9 (Project on Emerging Nanotechnologies, PEN 13, 2008), 
available at  www.nanotechproject.org/process/assets/files/6709/pen13.pdf. 
 294. Foote & Berlin, supra note 11, at 623. 
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Force.  Such reorganization will be difficult given the current docket in front of 
the FDA, but the Agency should nonetheless pursue changes in policy that are 
within its mandate and authority from Congress.  Although feasibility of a 
national coordinating body for nanotechnology legal and regulatory issues and 
FDA restructuring suffer from inevitable hurdles, the following two 
subsections suggest a variety of actions that the FDA could implement to 
initiate the process for improved information-gathering regarding 
nanomedicine products at the individual product review and approval stage. 
C. Uniform Information-Gathering Frameworks 
Perhaps the most critical steps to address nanotechnology involve the 
reassessment of concepts and measurements of safety utilizing the existing 
statutory and regulatory toolkit available.  Nanotechnology invariably raises 
new questions for the FDA’s risk versus benefit quantification and assessments 
due to lack of information regarding risk and public health effects.  As 
discussed in Part I.B, large-scale scientific uncertainty remains regarding short 
and long-term effects, including toxicity, effect of various exposure routes and 
routes of administration, possible unintended effects on non-target areas given 
the ability of nanoparticles to cross the blood-brain barrier, and interaction of 
various nanoparticles and nanomaterials within the human body.  Faced with a 
dearth of information regarding whether nanoparticles and nanomaterials have 
novel toxicological effects and would thus demand different measures to 
assure safety, the FDA has chosen to proceed to regulate based on existing 
frameworks, taking some small initial steps to gather drug-specific information 
via the internal MaPP detailed in Part III.C.2 and presenting considerations for 
industry as detailed in Part III.C.3. 
The existing statutory and regulatory scheme under which the FDA 
operates provides it with sufficient authority over nanomedicine products 
falling into the categories of drugs, medical devices, and biologics to develop 
nano-specific rules and regulations according to established administrative 
procedures.295  The problem turns on determining whether and to what extent 
nanoproducts warrant additional nano-specific rules or regulations.  In order to 
inform this determination, the FDA needs to gather and assess more 
information.  While several modifications to the process would enhance the 
FDA’s oversight and serve to gather much-needed information to allow the 
FDA to make such determinations, core concerns remain regarding the 
expertise necessary to assess safety and efficacy data, how to balance potential 
novel risks and benefits, and how to monitor possible short-term and long-term 
effects of nanomedicine products directly attributable to the nanoscale 
 
 295. Initial suggestions to improve FDA oversight of nanotechnology are presented by the 
author in Ramachandran et al., supra note 290. 
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properties.  Although the FDA has broad statutory authority to require pre-
market and post-market data submission for these three product areas,296 the 
FDA currently lacks the research budget and personnel to initially identify the 
amount and type of information to request and subsequently how to assess that 
data.297  The nascent state of understanding of properties and characterization 
of nanomaterials and nanoparticles, particularly within the human body, poses 
a major problem for the FDA. 
1. Full-Scale Safety and Efficacy Requirements 
As a threshold matter, the FDA should set forth regulations or policy 
indicating that nanotechnology products are subject to full-scale safety and 
efficacy requirements for the requisite product categories (i.e., drug, medical 
device, biologic) until there have been considerable research studies 
undertaken that examine the range of uncertainties and unknowns.  Where 
subject to the less rigorous approval pathways, there is concern that 
nanomedicine products may not satisfy traditional measures of equivalence (or 
similarity) that the FDA employs to deem one product as having the same 
safety profile because of the unique characteristics and properties exhibited at 
the nanoscale.  This approach is akin to the OCP’s decisions involving 
innovations that raise novel questions for regulation in the realm of 
combination products and sponsor requests for designation.298  This also 
responds to current controversy regarding the inadequacy of the 510(k) 
clearance process for medical devices and the successful completion of Phase 
IV studies for drugs approved via the Fast Track or accelerated process based 
on promise for treatment of life-threatening or serious diseases. 
Once the FDA has amassed a significant amount of information pursuant 
to the suggestions in Section IV.C.2 below, conclusions about continuance of 
such a nano-specific channeling into the most rigorous approval pathway can 
be based on robust scientific and technical information.  The FDA should use 
the nano-specific information gathered across the three Centers in joint 
considerations of whether to continue to require the full extent of safety and 
efficacy data by requiring a nano generic version of a non-nano pioneer drug to 
go through full NDA process (or a nano follow-on biologic of a pioneer to 
require a full BLA process), or at least require nano-specific information to be 
gathered in post-market studies; not allowing medical device products 
incorporating nanomaterials to be substantially equivalent to a predicate device 
unless that predicate device has substantially equivalent nanomaterials or 
nanoproperties (this goes to the scope of the “different technological 
 
 296. See supra Part II.A–C. 
 297. TAYLOR, REGULATING THE PRODUCTS OF NANOTECHNOLOGY, supra note 212, at 45–
47. 
 298. 21 C.F.R. §§ 3.1, 3.7 (2010). 
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characteristics”  that nonetheless pose no additional threat to safety or efficacy 
phrase within the statute); and requiring all nanoproducts to proceed through 
the BLA process rather than allowing measures of biosimilarity or 
interchangeability to factor into the process. 
2. Information-Gathering Mechanisms 
Even if the FDA does not implement policy requiring full-scale safety and 
efficacy for nanoproducts, the FDA should implement specific uniform 
information-gathering mechanisms.  The FDA should proceed in a parallel 
manner among all Centers pertaining to nanomedicine products—CDER, 
CBER, and CDRH.  Memoranda of Understanding among these Centers would 
help memorialize these parallel efforts, define key roles, interactions, and 
ultimate coordination processes for nanomedicine.  Information-gathering 
efforts should be installed that are uniform for NDAs (drugs), BLAs 
(biological products), and PMAs (medical devices).  Within the scope of its 
authority, the FDA should also mandate that the industry supply the nano-
specific information so the burden of information collection does not lie 
entirely with the FDA.  The FDA can use the CDER’s recent MaPP to develop 
language for other Center policies and procedures of tracking that information, 
as well as to help identify the information to be required by industry.  The 
FDA should consider whether the information reported to clinical trial online 
databases should include nano-specific information.  In appropriate 
circumstances, the FDA should utilize relevant regulations and statutory 
provisions to request post-market studies directed toward the nanoparticle or 
property of the product, such as REMS and new safety information provisions 
discussed in Section II.A. 
To assist in this endeavor, the FDA needs to utilize its scientific advisory 
network of experts; request information from scientists and the public in the 
form of announcements in the Federal Register, public meetings, forums, and 
other opportunities to identify relevant issues; and develop mechanisms to 
collect, analyze, characterize, and mine this information.  The FDA has begun 
to do this, having sponsored several public meetings, urging research into 
characterization and measurement methods, and initiating an internal process 
in the CDER to begin tracking nanodrugs.299  However, this approach has been 
piecemeal, with little coordination yet even among Centers within the FDA, let 
alone collaboration with other federal agencies.  It also fails to take advantage 
of the FDA’s authority to request specific information about a product prior to 
approval, or clearance of that product. 
For those nanomedicine products already approved or cleared that were not 
subject to the most rigorous pre-approval processes, the FDA should also 
 
 299. See supra Part III. 
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request additional information from the manufacturer or sponsor in order to 
track and assess those nanospecific properties and characteristics.  Efforts 
should also loop into other FDA Centers as well, including the CFSAN 
(regulating foods, dietary supplements, and cosmetics) and the Center for 
Veterinary Medicine. 
CONCLUSION 
The FDA engages in a delicate balance between protecting the public 
health and safety and promoting advancements in medicine and health care.  
Technological innovation often outpaces oversight by specialized scientific 
federal agencies tasked with regulating the resulting products and processes.  
Nowhere is this lag between innovation and regulatory response more 
prevalent than the realm of nanotechnology, a spectrum of disciplines and 
applications that integrates unique and novel properties.  Relevant specifically 
to the FDA is nanobiotechnology and nanomedicine, blending chemical, 
mechanical, and biological properties in a way that stretches existing oversight 
frameworks for drugs, medical devices, and biologics.  While nanotechnology 
raises problems for oversight, this Article has suggested several approaches for 
the FDA to begin assessing and responding to the challenges.  These 
encompass a variety of coordinating and collaborative efforts coupled with the 
use of authority in the context of increased information gathering from industry 
and post-market monitoring. 
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FIGURE 1: EXAMPLES OF FDA-APPROVED DRUGS UTILIZING NANOSCALE 
PROPERTIES OR MATERIALS300 
 
 
Product 
 
 
Indications 
 
 
Company 
 
Formulation 
Description 
 
Original 
Approval 
Doxil Ovarian cancer, 
breast cancer, and 
AIDS-related 
Kaposi’s sarcoma 
OrthoBiotech 
Products, LP 
Liposomal 
doxorubicin  
NDA 
November 1995 
(accelerated 
approval) 
DepoCyt Lymphomatous 
meningitis 
 
Pacira  Liposomal 
cytarabine 
 
NDA 
April 1999 
(accelerated 
approval)  
Rapamune Immunosuppressant 
for prevention of 
organ rejection in 
renal transplant 
patients (13 & 
older) 
Wyeth 
 
Nanocrystalline 
sirolimus 
 
NDA 
September 
1999 
Emend 
(Aprepitant) 
Prevents nausea and 
vomiting induced 
by chemotherapy 
Merck & Co.  Nanocrystalline 
aprepitant 
NDA 
March 2003 
 
Estrasorb Topical soy-based 
estrogen therapy for 
treatment of 
menopausal hot 
flashes 
Graceway 
 
Estradiol in micellar 
nanoparticles 
 
NDA 
October 2003 
Abraxane Breast cancer Abraxis 
Bioscience 
 
Albumin-bound 
paclitaxel  
NDA 
January 2005 
Emend 
(Fosaprepitant 
Dimeglumine) 
Prevents nausea and 
vomiting induced 
by chemotherapy 
 
Merck & Co. Lyophilized 
fosaprepitant 
dimeglumine 
NDA 
January 2008  
 
  
 
 300. Information adapted from Paradise et al., supra note 14, at 410–17; Paradise, supra note 
235, at 203–207. 
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FIGURE 2: EXAMPLES OF FDA-APPROVED MEDICAL DEVICES UTILIZING 
NANOSCALE PROPERTIES OR MATERIALS301 
 
 
Product 
 
 
Indications 
 
 
Company 
 
Formulation 
Description 
Original 
Approval 
Information 
Simile Nano-
Hyrbid 
Composite 
Dental material Pentron 
Laboratory 
Silica-zirconia 
nanoparticle filler 
510(k) 
January 2003 
 
Nano-Ticrown Dental material Nano-Write 
Corporation 
Nanostructured 
titanium/titanium 
nitride material  
510(k) 
June 2003 
TiMesh Tissue 
reinforcement and 
hernia repair 
GfE 
Meizintechnik 
Titanium 
nanomaterial 
510(k) 
September 
2003 
 
Vitoss Bone graft 
substitute 
Ortho Vita, 
Inc. 
Nanoparticles 510(k) 
December 2003 
Prime & Bond 
NT 
Dental bonding 
agent 
Dentsply 
International 
Nanometer sized 
bonding agent 
510(k) 
February 2005 
ACTICOAT Antimicrobial 
wound dressing for 
burns, graft sites, 
and ulcers 
Smith & 
Nephew 
Utilizes Silcryst 
silver nanocrystals 
technology 
(licensed from 
NuCryst) 
510(k) 
April 2005 
On-Q Silver 
Soaker 
Antimicrobial 
catheter 
i-Flow 
Corporation 
Treated with 
SilvaGard (licensed 
from Acrymed) 
510(k) 
November 2005 
AcryDerm Antimicrobial 
wound gel 
Acrymed, Inc. Polyurethane 
adhesive using 
SilvaGard silver 
nanoparticle 
technology  
510(k) 
October 2006 
Silcryst Antimicrobial 
wound cream 
NuCryst Nanocrystalline 
silver cream 
510(k) 
July 2007 
 
ASAP Wound 
Dressing 
Topical cream American 
Biotech Labs 
Coated with 
nanosilver 
510(k) 
April 2009 
 
  
 
 301. Paradise et al., supra note 14, at 415–17; Press Release, American Biotech Labs, 
American Biotech Labs(R) Obtains FDA Approval for New Wound Care Gel Product (Apr. 14, 
2009), available at http://www.reuters.com/article/2009/04/14/idUS215860+14-Apr-2009+PRN 
20090414. 
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